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Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the Swedish Work Environment
Authority (SWEA). In most cases a scientific basis is written on request from the SWEA.
The Criteria Group shall not propose a numerical occupational exposure limit value but,
as far as possible, give a dose-response/dose-effect relationship and the critical effect of
occupational exposure.
In searching of the literature several databases are used, such as RTECS, Toxline,
Medline, Cancerlit, Nioshtic and Riskline. Also information in existing criteria documents
is used, e.g. documents from WHO, EU, US NIOSH, the Dutch Expert Committee for
Occupational Standards (DECOS) and the Nordic Expert Group (NEG). In some cases
criteria documents are produced within the Criteria Group, often in collaboration with
DECOS or US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariat or by a scientist appointed
by the secretariat. The author of the draft is indicated under Contents. A qualified
evaluation is made of the information in the references. In some cases the information can
be omitted if some criteria are not fulfilled. In some cases such information is included in
the report but with a comment why the data are not included in the evaluation. After
discussion in the Criteria Group the drafts are approved and accepted as a consensus
report from the group. They are sent to the SWEA.
This is the 26th volume that is published and it contains consensus reports approved by
the Criteria Group during the period July 2004 through September 2005. These and
previously published consensus reports are listed in the Appendix (p 73).
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1Consensus Report for Hydrogen Fluoride,
Aluminum Trifluoride, Ammonium
Fluoride, Calcium Fluoride, Potassium
Fluoride, Sodium Fluoride
September 15, 2004
This report is an update of the consensus report published in 1984 (146), which
was based primarily on a criteria document from the Nordic Expert Group (72). It
is based partly on an IPCS document (168). The EU published a risk assessment
report for hydrogen fluoride in 2001 (41).
Chemical and physical data. Occurrence
Hydrogen fluoride
CAS No: 7664-39-3
Formula: HF
Molecular weight: 20.01
Boiling point: 19.5 °C
Melting point: - 83 °C
Vapor pressure: 90 kPa
Conversion factors: 1 mg/m3 = 1.2 ppm
   (20 °C, 101.3 kPa) 1 ppm = 0.8 mg/m3
Sodium fluoride
CAS No: 7681-49-4
Formula: NaF
Molecular weight: 41.99
Boiling point: 1704 °C
Melting point: 993 °C
Solubility in water: 42 g/l (20 °C)
Calcium fluoride
CAS No: 7789-75-5
Formula: CaF2
Molecular weight: 78.08
Boiling point: 2513 °C
Melting point: 1403 °C
Solubility in water: 0.016 g/l (20 °C)
2Ammonium fluoride
CAS No: 12125-01-8
Formula: NH4F
Molecular weight: 37.04
Sublimation: 100 – 125 °C
Solubility in water: 820 g/l (20 °C)
Potassium fluoride
CAS No: 7789-23-3
Formula: KF
Molecular weight: 58.10
Boiling point: 1505 °C
Melting point: 858 °C
Solubility in water: 920 g/l (20 °C)
Aluminum trifluoride
CAS No: 7784-18-1
Synonym: aluminum-fluoride
Formula: AlF3
Molecular weight: 83.98
Sublimation point: 1291 °C
Solubility in water: 5 g/l (20 °C)
Fluorine (F) is a widely occurring element belonging to the halogen group, which
also includes chlorine (Cl), bromine (Br), iodine (I) and astatine (At). The name
is derived from early use of calcium fluoride as a flux (Latin fluere, fluxus: flow)
(56). The salts of hydrofluoric acid are called fluorides. Fluorine is a pale yellow-
green, irritating gas. It is extremely reactive and therefore seldom occurs in ele-
mental form. Solutions of the water-soluble fluorides are usually acidic; only
potassium fluoride has a weak alkaline reaction. Heating or contact with strong
acids results in formation of hydrogen fluoride.
Anhydrous hydrogen fluoride is a colorless, sharp-smelling gas that occurs
primarily as (HF)6, although at higher temperatures it commonly occurs as
the monomer (HF). Anhydrous hydrogen fluoride reacts strongly with sodium
hydroxide, sulfuric acid and several organic compounds, and dissolves readily
in water, forming hydrofluoric acid. Hydrogen fluoride is usually produced from
fluorite by treating it with concentrated sulfuric acid. Anhydrous hydrogen
fluoride in turn is used as a raw material in production of various organic and
inorganic fluoride compounds: fluorocarbons, synthetic cryolite (Na3AlF6),
aluminum trifluoride (AlF3), gasoline alkylators etc., and also in the production
of elemental fluorine. Hydrogen fluoride is also needed for synthesis of uranium
tetrafluoride (UF4) and uranium hexafluoride (UF6), both of which are used in the
atomic power industry. Hydrofluoric acid is used in oil refining, as a catalyst in
3condensation reactions, as a preservative, for etching glass, semiconductors and
metals, for tanning leather, and for removing rust and enamel from metal objects.
Hydrogen fluoride can occur as an air pollutant in aluminum smelters and in
brick, tile and ceramic production (18). Commercial hydrofluoric acid usually
contains up to 53% hydrogen fluoride. It etches glass and dissolves quartz and
silicates.
Sodium fluoride is a colorless or white powder, moderately soluble in water.
Concentrated solutions are highly corrosive. Sodium fluoride is usually produced
from hydrofluoric acid and sodium carbonate or sodium hydroxide (114). Sodium
fluoride is used in steel and aluminum production (as a flux), acid baths, ceramic
enamels, glass production, casein glue, detergents, paper coatings and insecti-
cides; as a preservative; and for wood impregnation and fluoridation of drinking
water (not in Sweden). Dilute solutions (0.02 – 0.2%) are used as mouthwash to
strengthen tooth enamel (58, 114).
Calcium fluoride is a colorless solid, relatively insoluble in water as well as
in dilute acids and bases (about 3000 times less soluble than NaF) (99, 114). It
occurs in fluorite, a mineral that can be 60 – 97% calcium fluoride (168). Calcium
fluoride is used in fluxes for production of steel and aluminum, in glass and
enamel, and also in production of hydrogen fluoride and hydrofluoric acid (114).
Calcium fluoride is also used in basic electrodes for welding (137, 138).
Ammonium fluoride occurs as white to colorless crystals resembling sand. It
dissolves easily in water, forming a weak acid. It is used as a preservative and in
wood impregnation, printing, coloring various materials, glass etching and moth
repellents (158).
Potassium fluoride is a white, crystalline, caustic powder. It is soluble in water
and weakly alkaline. On contact with strong acids it forms hydrogen fluoride. It
is used to etch glass, as a preservative and insecticide, in production of elemental
fluorine, and in fluxes for metal production (158).
Aluminum trifluoride, which is a Lewis acid, is a white, odorless but irritating
solid that is only sparingly soluble in water (5 g/l). It is used in glass, porcelain
and enamel; fluxes for welding and soldering; and in production of aluminum and
aluminum silicate. The toxic effects of aluminum trifluoride are due not only to
the fluoride, but to the aluminum also (93).
Uptake, biotransformation, excretion
Most occupational exposure is due to inhalation of dust and gas containing
fluoride (63). Fluorides occur in industrial environments primarily in the form
of dust, which with inhalation can penetrate the lungs – how deeply depends on
particle size and solubility. The absorption of particulate fluorides increases
with their solubility (84, 167). Autopsies of two cryolite workers showed an
accumulation of fluorine in lung tissue due to inhalation of cryolite dust (10.8
4and 79.2 mg F/100 g dry weight; unexposed control 0.73 mg F/100 g dry weight)
(127).
Rats exposed by inhalation to 36 – 176 mg F-/m3 absorbed nearly all of it (110).
The situation seems to be about the same for people (99).
Hydrogen fluoride has a permeability coefficient near that of water (P = 1.4 x
10-4 cm/s) measured in a lipid membrane consisting of lecithin and cholesterol
(13). Skin and other tissues are rapidly permeated by diffusion of undissociated
hydrogen fluoride, and effects on other organs can be the same as with inhalation.
The rapid absorption seen after skin exposure to hydrogen fluoride may be partly
a consequence of the corrosive nature of the substance, which damages blood
vessels (168). After uptake, free fluoride ions bind to calcium and magnesium
ions, forming insoluble salts (13, 157). There are no data from which to calculate
quantitative skin uptake.
Soluble fluorides (e.g. sodium fluoride), once ingested, are absorbed rapidly
and almost completely. Plasma fluoride concentration increases after only a few
minutes, and a plasma peak proportional to the amount of intake usually can be
measured within 30 minutes (36). Most fluoride is absorbed as hydrogen fluoride,
which forms on contact with gastric acid (162). Hydrogen fluoride in aqueous
solution diffuses through biological membranes mostly as the undissociated
monomer HF (163). Absorption is by passive diffusion in both stomach and
intestines. The absorbed amount can be considerably reduced by complex
formation with e.g. calcium, magnesium or aluminum (161). In a bioavailability
study, healthy volunteers were given 4 mg fluoride, as either calcium fluoride or
sodium fluoride, in the form of tablets. They were monitored for 6 hours, with
sampling after 0.5, 0.75, 1.0, 1.25, 2.0, 4.0 and 6.0 hours. After the sodium
fluoride intake there was a rapid increase of plasma fluoride level and a peak after
about 1 hour, but no increase in plasma fluoride level was seen in the subjects
who had taken the calcium fluoride (3). Other sources, however, report a fluoride
absorption of 67% for calcium fluoride (83).
The biological half time for fluoride in blood after oral intake of sodium
fluoride is reported to be about 4 hours, although it seems to vary with the amount
of intake (36). Fluoride is not metabolized, although it may form complexes with
e.g. calcium or aluminum. It is distributed in blood to all organs in the body, and
is reversibly bound to bone in the form of fluoride apatite. Bones and teeth contain
99% of all the fluoride in the body (53, 168). Volunteers were given 18F by
injection, and 1 hour later 40% of the dose was in extracellular fluid, 20% had
been excreted, and 40% had been taken up in the tissues (including 2.5% in the
red blood cells) (64). Fluoride also accumulates in hair and nails (25, 78, 165).
The most important elimination pathway is via the kidneys, which excrete 40 –
60% of the daily fluoride intake (161); a further 5 – 10% of daily intake is
eliminated in feces. Elimination in perspiration is apparently low (63), and
only a minimal amount of fluoride makes its way into breast milk (38).
5Biological exposure measurements
With both experimental and occupational exposure to fluoride, and for both oral
and inhalation exposure, there is a relatively good correlation between exposure
and fluoride levels in urine and blood (35, 39, 90, 161, 167).
Persons not occupationally exposed usually have fluoride levels in urine that are
about the same as those in their drinking water (166). A survey of drinking water
in Sweden, made during the 1960s, revealed that about 500,000 people drank
water with a fluoride content above 0.8 mg/l (40 μmol/l) (140).
With occupational exposure to several types of fluoride compounds, there
is a linear relationship between fluoride in air and in urine. The regression
coefficients, however, differ with the compound in question. With exposure to
hydrogen fluoride from hydrofluoric acid baths, urine fluoride level rose by 4.6
mg/l when fluoride in air rose by 1 mg/m3 (63). For welding with basic electrodes
containing calcium fluoride, urine fluoride level rose by 1.5 mg/l when fluoride
in air rose by 1 mg/m3 (137). In both of these studies, urine levels were measured
after a workshift. The total amount of fluorides in urine of aluminum smelter
workers (24-hour measure) rose by 3.9 mg/l when the fluoride in air increased by
1 mg/m3 (32). It is reasonable to assume that these differences reflect differences
in the solubility of different fluoride compounds.
In Germany there are biological exposure limits for urine content of fluorides as
indicators of exposure to hydrogen fluoride and inorganic fluorides. The limit for
fluorides is 7.0 mg/g creatinine after a workshift and 4.0 mg/g creatinine before a
workshift (30).
The concentrations in saliva (37, 119, 164), hair and nails (25, 78, 165) have
also been proposed as exposure measures, but there is limited information on the
reliability of these methods (168).
It has also been proposed that fluoride in urine could be used as an exposure
indicator for particles in smoke from welding with basic electrodes, since the
smoke contains 18 – 20% fluorides (137).
Toxic effects
Effects on skin, eyes and respiratory passages
Hydrogen fluoride, hydrofluoric acid and acidic aqueous solutions of fluorides
all have an irritating and corrosive effect on skin, eyes and mucous membranes.
Machle et al. (94) exposed two volunteers to hydrogen fluoride. The highest
concentration they could endure for more than one minute was 100 mg HF/m3.
Their skin began stinging within a minute, and they also reported irritated eyes
and respiratory passages. A concentration of 50 mg HF/m3 caused pronounced
irritation of eyes and nose and stinging in the upper respiratory passages. A
concentration of 26 mg HF/m3 could be tolerated for several minutes, although
slight stinging in nose and eyes was reported (94). One volunteer exposed to an
average of 1.2 mg HF/m3 (about 0.8 – 1.7 mg HF/m3), 6 hours/day, 5 days/week
for 15 days, endured the exposure with no notable effects on respiratory passages,
6but the subject reported a slight burning sensation on the face (no skin reddening).
Five volunteers were exposed to hydrogen fluoride in air concentrations averaging
2.1 – 3.9 mg/m3, 6 hours/day, 5 days/week for up to 50 days; symptoms resulting
from the exposure were burning sensations in skin, eyes and nose, and reddened
and flaking skin resembling mild sunburn. No effects on lower respiratory pas-
sages were reported (83, 84). Exposing the eyes to higher concentrations results
in redness, edema, photophobia and corneal necrosis (72).
Hydrogen fluoride and hydrofluoric acid are extremely caustic, and skin contact
results in intense pain after a dose-dependent latency time. Damage to deep tissues
and bone can occur with little effect on overlying skin. With hydrofluoric acid that
is over 70% HF the effects appear immediately, whereas with concentrations
below 50 – 60% it can take several hours for symptoms to appear (72). Skin
uptake can result in severe and even fatal systemic poisoning (157). There are
reports of non-lethal but severe poisonings resulting from industrial accidents. A
30-year-old man who was exposed to about 5 g anhydrous hydrogen fluoride on
2.5% of his skin had a blood fluoride value of <3 mg/l both 4 and 10 hours after
the accident (12). Systemic poisoning in adults has also been reported after
exposure of 2.5% of skin to 60% hydrofluoric acid (initial serum fluoride level
7.1 mg/l) and after exposure of 22% of skin to 70% hydrofluoric acid (initial
serum fluoride level 6 mg/l) (55). In another case of severe systemic poisoning
of an adult, about 5% of skin was exposed to anhydrous hydrogen fluoride (11).
There is a case report of a fatal poisoning of a 62-year-old man after skin
contact with hydrofluoric acid (concentration unknown): 20% of his skin was
damaged (55). Another fatal case was reported in which 2.5% of the skin was
exposed to anhydrous hydrogen fluoride: serum fluoride level was reported to be
3 mg/l (150). A 23-year-old man died after 9 – 10% of his skin had been damaged
by 70% hydrofluoric acid. His postmortem serum fluoride value was 4.17 mg/l
(98). Two men, 50 and 60 years old, died after accidental exposure of face, chest,
arms and legs to 70% hydrofluoric acid (15). A 37-year-old man died after about
8% of his skin was burned by about 150 ml 70% hydrofluoric acid (57). A 61-
year-old man died after a 70% hydrofluoric acid solution was spilled on 8% of his
skin. Four hours after the accident his serum fluoride value was 9.42 mg/l (111).
It has also been suspected that a particular type of skin change, Chiazzola
maculae, which has been observed in persons living in an industrial area with
fluoride emissions, might be caused by airborne fluorides. In a wide-ranging
examination of the literature, however, Hodge and Smith (62) concluded that
there is no support for this suspicion.
Tracheobronchitis, dyspnea, pulmonary edema and pulmonary hemorrhage,
sometimes with fatal outcome, have been reported after inhalation of high
hydrogen fluoride concentrations from accidental emissions (28, 115). Pulmonary
edema has also been reported after absorption of hydrogen fluoride through the
skin (150).
Single exposures to high doses of irritative substances can trigger an asthma-
like disease – RADS (Reactive Airways Dysfunction Syndrome) – in persons with
previously healthy respiratory systems (154). A 26-year-old, previously healthy
7woman was exposed to HF while she was cleaning her toilet with a water-based
rust remover containing 8 – 9% HF. After 1.5 to 2 minutes of scrubbing, her eyes,
nose and mouth began to sting and she was having difficulty breathing. Her
condition was initially regarded as RADS. It apparently developed into a chronic
illness, since 2 years after the incident she was still being treated with broncho-
dilators and cortisone, and had difficulty breathing with exertion and at night (43).
A new process for producing aluminum-fluoride was developed in a Swedish
factory in the mid-1970s: fluosilic acid was heated with aluminum trihydrate in
special ovens. During the development phase there were technical problems
resulting in emissions from the ovens. It is reported that about 20% of the work-
force of 35 – 40 persons suddenly developed problems with nocturnal wheezing
and dyspnea. In the 1975-77 period there were 15 new cases of asthma, often after
only a month or so of exposure, that were diagnosed during the following years at
a lung clinic where diagnosis included methacholine tests. Dust measurements
were taken around aluminum-fluoride production in the years 1975-77: stationary
monitors showed air levels up to 53 mg/m3 (n = 289, average 1975:15.8, 1976:
3.6, 1977: 1.0 mg/m3) and personal monitors registered concentrations up to
13.5 mg/m3 (n = 15, average 1975: 5.5, 1976: 2.6, no personal monitors used in
1977). About 25 – 30% of the dust had a particle size <5 μm. There was also a
case report of a repairman who developed asthma the day after a heavy exposure.
In two cases, provocation with aluminum-fluoride triggered no asthma symptoms.
The authors attribute the appearance of asthma to the aluminum-fluoride
exposure. It is clear, however, that the patients were simultaneously exposed to
oven gases of unidentified composition, which might well be relevant. In 1977 the
work environment was improved and the average exposure dropped to 0.4 – 1.0
mg/m3, and in 1978 – 1982 there were 2 new cases of asthma (136).
Twenty healthy volunteers were exposed to various concentrations of HF in
an exposure chamber for 60 minutes. Two of the subjects had hay fever and one
of these had a high level of IgE (210 kU/l) (no information on which exposure
group(s) contained these two subjects). The participants were divided into three
exposure groups: 0.2 – 0.6 mg/m3 (n = 9), 0.7 – 2.4 mg/m3 (n = 7) and 2.5 – 5.2
mg/m3 (n = 7). The subjects were exposed only once, except for three persons
who were exposed twice with three months between exposures. The participants
graded their symptoms on a special questionnaire before and after the exposure.
Symptoms involving eyes and upper and lower respiratory passages were graded
from 0 (“no symptoms”) to 5 (“most severe”). Upper respiratory symptoms
increased with higher exposure. In the group with the lowest exposure, slight
symptoms were reported by 4 of 9 (p = 0.06), in the middle group by 6 of 7 (p =
0.10) and in the group with highest exposure all 7 subjects reported symptoms
(four ranked their symptoms 1 – 3, and three ranked their symptoms above 3) (p =
0.02). There was no clear dose-response relationship for symptoms involving eyes
and lower respiratory passages. The reported severity of the symptoms was also
included in the statistical processing. Nearly all the symptoms had disappeared
four hours after the exposure. Lung function was measured before and after the
8exposure, and no change in FEV1 was observed. A slight but significant reduction
of FVC was seen in the low-exposure group, but since it was not observed in the
other groups it can not be interpreted as an effect of the exposure (90). There were
few subjects in this study, and they were not given a null exposure to allow them
to become accustomed to the exposure chamber. It is therefore difficult to assess
the effect of the lowest exposure. The most probable LOAEL was estimated to be
0.7 – 2.4 mg/m3.
When the same subjects (n = 19) were exposed to <0.6, 0.7 – 2.4 or 2.5 – 5.2
mg/m3 hydrogen fluoride for one hour, the number of CD3-positive cells in the
bronchial part of bronchial lavage fluid increased at the two higher exposures.
Myeloperoxidase and inteleukin-6 increased at the highest exposure; this was
regarded as an expression of an inflammatory reaction (91).
Seven of ten healthy volunteers who were exposed to 1 hour of hydrogen
fluoride inhalation (3.3 – 3.9 mg HF/m3) reported experiencing discomfort in nose
and throat. Nasal lavages performed before and immediately after the exposure
and 1.5 hours later revealed a significant increase in the numbers of neutrophilic
granulocytes, total number of cells, tumor necrosis factor-alpha (TNF-α) and
various eicosanoids, and an elevated concentration of antioxidants (92).
As early as 1936, occupational asthma was described in connection with
electrolytic production of aluminum. This form of asthma was usually referred
to as “potroom asthma” (45). Many studies of workers in aluminum smelters
(electrolytic production) report effects on respiratory passages, including reduced
lung capacity, irritation, asthma, coughs, bronchitis, dyspnea and emphysema.
Among the substances these workers were exposed to were airborne fluorides
(168). A correlation between fluoride exposure and the occurrence of asthma-like
symptoms (dyspnea and wheezing) was observed many years later (77). In 26
persons with asthma-like symptoms there was a correlation between fluoride
levels in plasma (as a measure of exposure) and bronchial response to metha-
choline (142). Electrolytic production of aluminum is associated with exposure to
a large number of airborne substances, including carbon monoxide, sulfur dioxide,
hydrogen fluoride, polycyclic hydrocarbons and particles containing aluminum
and fluorides (1), as well as small amounts of metals, including nickel, chromium
and vanadium (141).
In a study of 370 potroom workers at an aluminum smelter it was found that
complaints of bronchial symptoms and work-related asthma-like symptoms were
more frequent among workers exposed to total fluoride levels >0.5 mg/m3 than
among workers exposed to <0.5 mg/m3. Lung function studies were made, and no
significant difference could be found. These workers were also exposed to sulfur
dioxide. The prevalence of respiratory symptoms was independent of the level of
dust exposure (141).
A historical cohort study of 5627 workers at two aluminum smelters in Norway
contains an analysis of causes of death between 1962 and 1995. An association
was found between emissions in the potrooms – which included fluorides
9(calculated to have been between 0.1 – 1.7 mg/m3), sulfur dioxide and aluminum
oxide dust – and death due to chronic obstructive lung disease and asthma (128).
Chan-Yeung et al. (17), in a study of 797 workers (+713 workers in the office
and casting departments with no significant exposure to air contaminants as
controls) at an aluminum smelter, found that workers who spent >50% of their
shift in the potrooms had higher frequencies of coughing and wheezing and
significantly lower FEV1 and maximum mid-expiratory flow values than the
control group. The total fluoride level was reported to be 0.48 mg/m3. These
workers were also exposed to sulfur dioxide, aluminum oxide, carbon monoxide
and benzo-[a]-pyrene (17).
Lung function and bronchial reactivity were measured in 38 potroom workers
exposed to airborne fluorides and aluminum oxide. The workers were divided
by job description into low-, medium- and high-exposure groups. Significant
elevations in obstructive lung function changes and reduced diffusion capacity
were seen when the potroom workers were compared to the control group.
There was no observed difference between the high- and low-exposure groups.
Methacholine tests revealed no increase in bronchial reactivity. The fluoride
exposure was reported to be 0.31 mg/m3 (85).
A study made in three aluminum smelters in Norway showed a low but
significant correlation between fluoride in air and changes in lung function (FEV1)
during a workshift, and between fluoride concentrations in air and in urine. The
air content was <2.5 mg/m3, and the average post-shift urine concentration was
<5.1 mg/l. Exposure measurements were also made for sulfur dioxide and carbon
monoxide (71).
Elevated occurrences of respiratory problems and effects on lung function,
sometimes with asthma, have thus been demonstrated in several studies of
aluminum-fluoride production and in aluminum smelters (77, 136, 142). Since
there was simultaneous exposure to several other substances including oven
gases, the role of fluoride compounds in the reported health effects can not
be determined with certainty. Although there were demonstrated correlations
between fluoride in air and in urine, simultaneous exposure to other respiratory
irritants may have caused or contributed to the health problems. No sensitizing
mechanism has been described.
Direct application of sodium fluoride (0.5 or 1.0% in distilled water) to abraded
skin of rats for 24 hours had effects ranging from superficial necrosis to edema
and inflammation (40). Application of a 2% solution of sodium fluoride in water
to the eyes of rabbits caused epithelial defects and conjunctival necrosis (54).
Effects on bones
High and prolonged uptake of fluoride leads to skeletal fluorosis, which is
characterized by osteosclerosis (increased mineralization of the bones). This
was first described in 1932 as an occupational disease of cryolite workers (109).
Osteosclerosis itself is seldom a problem, but it can lead to brittle bones and a
higher frequency of fractures, and a concurrent calcification of the tendons can
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be painful and restrict movement (161). In a study of workers at an aluminum
smelter, no osteosclerotic changes were found after 10 – 43 years of exposure
to fluorides. Fluorine concentrations measured in urine were 2.78 mg/l before a
workshift and 7.71 mg/l afterward (average values) (31). Chan-Yeung et al. (16)
studied 2066 employees at an aluminum smelter in Canada. The subjects were
divided into groups by fluoride exposure: 570 persons who spent at least 50% of
their working time in the potroom were labeled “high-exposure” and 332 who
spent less than 50% of working time in the potroom were labeled “medium-
exposure”. A group of 284 workers (e.g. welders) was labeled “mixed-exposure”.
There were also an unexposed internal control group consisting of 880 office
workers and an external control group of 372 railroad workers. Airborne fluorides
were measured with personal monitors. Fluoride concentrations measured in urine
of the control group (total airborne fluorides 0.053 mg/m3) were 1.2 mg/l before a
workshift and 1.3 mg/l after a workshift (mean values); 1.9 mg/l (before) and 2.7
mg/l (after) in the high-exposure group (total airborne fluorides 0.48 mg/m3); 1.4
mg/l (before) and 1.8 mg/l (after) in the medium-exposure group (total airborne
fluorides 0.12 mg/m3); and 1.5 mg/l (before) and 1.8 mg/l (after) in the mixed-
exposure group (total airborne fluorides 0.46 mg/m3). Levels of fluoride in urine
were correlated to exposures. Hips were x-rayed in a subgroup of 136 workers
in the high-exposure group, 41 in the medium-exposure group who had been
employed in the potroom for more than 10 years, and 33 unexposed workers
(internal controls). The x-rays showed slight indications of increased skeletal
density in a few of those who had been exposed for more than 10 years. However,
there was some disagreement among the radiologists as to how the x-rays should
be interpreted . The authors concluded that there were no definite cases of skeletal
fluorosis among the potroom workers at an aluminum smelter who were exposed
to about 0.48 mg fluoride/m3 for at least 50% of their time at work. There were no
observed differences among the groups with regard to occurrence of back and
joint problems. Blood tests showed no indications of renal, hepatic or hemato-
poietic effects (16). In a review of older studies, it was concluded that the risk for
occurrence of diagnosable osteosclerosis was high if the air concentration of
fluoride at a workplace exceeded 2.5 mg/m3 and/or fluoride in urine exceeded
9 mg/liter. However, workplaces where fluoride concentrations were below 2.5
mg/m3 (and fluoride in urine below 5 mg/l) didn’t seem to cause osteosclerosis
(62). In a study in the phosphate industry, somewhat higher bone density was seen
in 17 of 74 persons. Their average exposure was 2.81 mg F/m3 and average length
of employment was 14.1 years. No clinical symptoms were reported (29). In a
Polish study of 2,258 workers at an aluminum smelter, skeletal changes were
related (clinically and radiologically) to a qualitative ‘exposure index’ calculated
from length of employment (average 17.6 years) and extent of levels exceeding
the exposure limit (monitoring showed values up to 4 times higher than the Polish
threshold limit of 0.5 mg HF/m3) in various parts of the plant. The prevalence of
skeletal changes was positively correlated to the ‘index of exposure-years’. More
pronounced changes were documented in older workers (26).
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The connection between skeletal fluorosis and work-related intake of 0.2 – 0.35
mg F/kg body weight/day (via inhalation of cryolite dust) for several years was
studied in cryolite workers in Copenhagen. Workers with mild osteosclerosis had
been employed for an average of 9.3 years; pronounced cases had been employed
for an average of 21.1 years (127). Osteosclerotic changes were documented in a
person who had worked for 16 years with hydrogen fluoride production; 24-hour
urine concentration was reported to be about 15 mg F/l (169). The relationship
between hip fractures and fluoride in drinking water was examined in a retro-
spective cohort study in Finland. The study covered 144,627 persons who were
born between 1900 and 1930 and who had lived in the same village without
municipal water service for at least 13 years (1967 – 1980). The participants were
divided into 6 groups according to the fluoride concentration in their drinking
water. The total daily fluoride intake in the cohort was estimated to be 0.6 –
3.7 mg/day (including food and other fluoride sources such as toothpaste). The
occurrence of hip fractures between 1981 and 1994 was established by checking
hospital records. No association was found between fluoride concentration and
occurrence of fractures, among either men or women, if all age groups were
considered together. However, significantly elevated relative risk of hip fracture
was seen in the highly exposed (3.7 mg F/day) women in the 50 – 65 age group
when they were compared with the low-exposure (0.6 mg F/day) group (81).
The relationship between fluoride in drinking water and hip, vertebral and
total fractures after age 20 was examined in a study of rural Chinese. The study
covered 8,266 people from six regions with different fluoride concentrations in
drinking water. The participants had lived in the same village for at least 25 years
and were 50 years old or older. Drinking water and food were reported to be
the only relevant sources of fluoride. Estimated daily fluoride intakes in the six
regions were 0.73, 1.62, 3.37, 6.54, 7.85 and 14.13 mg. One or more fractures
were reported by 531 persons: 526 of these were confirmed by x-rays, and 56 of
these were hip fractures. A group with medium exposure (3.37 mg F/day) had the
lowest number of fractures, and the differences between this group and the lowest
(0.73 mg F/day) and highest (14.13 mg F/day) exposure groups were statistically
significant. Analyses were also made of all fractures occurring after age 50: they
showed the same tendency, but the difference was statistically significant only for
the high-exposure group. The number of hip fractures was the same in the three
lowest exposure groups, but then rose with rising fluoride exposure, and in the
highest exposure group the increase was significant. For vertebral fractures there
was no observed difference between the groups (89).
WHO has concluded that studies from India and China indicate some increase
in risk of skeletal effects with intake (primarily via food and drink) of over 6 mg
F/day. Significant effects were seen at intake of 14 mg F/day (168).
Skeletal changes seem to be slowly and at least partly reversible after fluoride
exposure is stopped (53, 127).
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Other toxic effects
Fluoride has high acute toxicity. The lowest potentially toxic oral dose is calcu-
lated to be 5 mg F/kg body weight (159). A definitely lethal dose for an adult
weighing 70 kg is reported to be 5 – 10 g NaF (32 – 64 mg F/kg body weight)
(61), but deaths among adults have been reported at much lower doses (<18 mg
F/kg) (49). Among children, severe poisonings and several deaths have been
reported in connection with non-therapeutic intake of tablets containing sodium
fluoride, and in one case a 2-year-old child died after oral intake of about 4 mg
F/kg (34). Deaths have also been reported after consumption of other products
containing fluoride (wheel cleaner containing ammonium bifluoride) (75, 112).
Consumption of fluorides can have a range of acute effects: nausea, vomiting,
stomach cramps, diarrhea, fatigue, drowsiness, coma, spasms, cardiac arrest and
death (9, 73, 150). Cardiac arrest is believed to be due to development of hypo-
calcemia and/or hyperkalemia (9, 10, 24). Several cases of cardiac arrest and
death have also been reported after skin contact with hydrogen fluoride (15, 55,
57, 98, 111). In one case, the patient died of heart failure due to necrotic cardiac
muscles 12 days after drinking half a shot glass of 17.3% hydrofluoric acid (42).
In animal tests to determine LC50 values, rats, rabbits and guinea pigs have been
exposed by inhalation to various concentrations of hydrogen fluoride. Rats were
found to be most sensitive (LC50 4142 mg/m3 for 5 minutes, 1092 mg/m3 for
60 minutes). Observed indications of toxicity were pronounced irritation of
conjunctiva, mucous membranes and respiratory passages. The animals that
survived the exposure recovered within a week. The animals that died had
pathological changes in lungs, kidneys and liver, and necroses and inflammation
in skin and mucous membranes (130). The LD50 for oral administration of sodium
fluoride is reported to be between 36 and 96 mg F/kg body weight for rats and
between 44 and 58 mg F/kg body weight for mice (160).
Fluoride apparently interferes with several enzyme systems, including cholin-
esterase and enzymes involved in glycolysis. This is regarded as a possible cause
of the neuromuscular weakness and CNS depression seen with severe poisoning
(9). Hypomagnesemia has also been observed following skin contact with
hydrogen fluoride (15, 131).
Fluoride in low doses has a documented protective effect against caries,
but chronic, high exposure leads to disruption in tooth mineralization (dental
fluorosis), since fluoride interferes with enamel formation in the tooth buds. It
shows up as white hypomineralized spots in the enamel, which in severe cases
can be fairly large holes (73). The spots can grow darker with age.
No increase of hematopoietic, hepatic or renal dysfunction was seen in 570
aluminum smelter workers with an average 79 months of exposure to 0.48 mg
fluoride/m3 and an average after-shift urine value of 2.7 mg F/l (16). Nor was
elevated occurrence of kidney disease seen in several epidemiological studies of
people (both children and adults) with long-term exposure to drinking water with
fluoride concentrations up to 8 mg F/l (47, 86, 125, 133). No indications of
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significant negative hematological, hepatic or renal effects were found in a study
of patients with osteoporosis. The patients (n = 163) had been taking about 60 mg
sodium fluoride/day (equivalent to a dose of 389 μg fluoride/kg body weight/day
for an adult weighing 70 kg) for 5 years (59). Yet another study examined post-
menopausal women with osteoporosis (n = 25) who had been taking 23 mg
fluoride/day (as sodium monofluorophosphate) for an average of 4.2 years (1.4
to 12.6 years). This equals a dose of 400 μg F/kg body weight/day for an adult
weighing 58 kg. Average urine content was 9.7 mg F/l and average blood content
0.17 mg F/l. No clinically significant effects on studied parameters could be
observed when blood and urine samples from the fluoride-exposed patients
were compared with samples from a control group (68).
Reports of fluoride hypersensitivity are mostly of an anecdotal nature (108,
122, 125). Reported symptoms include dermatitis, urticaria, inflamed mucous
membranes in the mouth, and gastrointestinal disturbances. Hypersensitivity to
dental care products containing fluoride might be caused by either sodium fluoride
or the color or taste additives (2).
High concentrations of fluoride in vitro (e.g. 10 mM NaF and 25 mM NaF)
have been observed to disturb a number of cell processes through their effect
on various enzymes and receptors (5, 107, 117, 120). The relevance of these
observations in vivo, however, is unclear.
Genotoxicity
The ability of fluorides – especially sodium fluoride (NaF) – to damage genetic
material has been tested in numerous systems, both in vivo and in vitro. There are
also data from examination of exposed people.
Table 1 presents studies on the ability of fluorides to cause genetic mutations
in bacterial tests (Salmonella typhimurium) and various mammalian cell lines in
vitro. In Ames’ tests with Salmonella, no mutagenic effect was observed even at
high sodium fluoride concentrations, either with or without addition of metabo-
lizing systems. However, mutagenic effects have been observed in some mam-
malian cell lines, especially at high concentrations of sodium fluoride.
Table 2 presents results from studies of the ability of fluorides to cause
structural or numeric chromosome changes, primary DNA damage, gene
conversion or meiosis disturbances in mammalian cells in vitro (Table 2a) and in
laboratory animals in vivo (Table 2b). Sodium fluoride has been shown to damage
genetic material in several cell lines (4, 116, 134, 155, 156). The picture is not that
simple, however: there are also negative results, even at high doses (46, 151, 153).
Nor are the results of in vivo tests entirely unequivocal. Most of the studies report
no effects even after high exposures (40, 60, 70, 79), but there are also reports of
effects at fairly low doses of sodium fluoride (121).
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Table 1. Results of in vitro mutagenicity studies with bacteria (Salmonella typhimurium)
and mammalian cells.
System Fluoride dose Effect tested Result Ref.
Salmonella F 0.1-2000 μg/plate histidine reversion Negative 96
Salmonella NaF
0.44-4421 μg/plate
histidine reversion Negative 87
Salmonella NaF
10-320 μg/plate
histidine reversion Negative 153
Mouse
lymphoma cells
L5178Y
NaF
200-800 μg/ml
4 h
thymidine kinase Positive at 300 μg/ml;
800 μg/ml caused cell
death
14
Mouse
lymphoma cells
L5178Y
KF
300-700 μg/ml
4 h
thymidine kinase Positive at 400 μg/ml;
700 μg/ml caused cell
death
14
Human
lymphoblastoid
cells
NaF
100-600 μg/ml
28 h
thymidine kinase,
hypoxanthine-guanine
phosphoribosyl-
transferase
(HGPRT assay)
Effects only at
concentrations resulting
in significant cell death
(12% survival)
23
Rat liver cells NaF
2-40 μg/ml
72 h
HGPRT assay Negative 153
There have been few studies of genotoxic effects on humans. In one study of
fluoride-exposed workers in a phosphate fertilizer plant in China, it was found
that the average frequency of sister chromatid exchanges (SCE) in lymphocytes
in peripheral blood was about 50% higher in these workers (n = 40) than in an
equally large group matched for age, sex and smoking habits (100). However,
during the study period the workers were exposed not only to fluorine (mostly
hydrofluoric acid and silicon tetrafluoride), 0.5 – 0.8 mg/m3, but also to phosphate
fog, ammonia and sulfur dioxide. Both ammonia and sulfur dioxide have been
shown to give rise to chromosome aberrations (102, 103, 104, 171, 172). No
information on the total amount of fluoride was presented. There was no
correlation between duration of employment (<5, 5 – 10 or >10 years) and
frequency of sister chromatid exchanges. In another study with the same exposure
conditions (101), of workers (n = 40) at the same fertilizer plant, both chromo-
some aberrations and micronuclei in circulating blood lymphocytes were higher
than in 40 controls matched for age, sex and smoking habits.
In the previously mentioned study (under Other toxic effects) of post-
menopausal women with osteoporosis (n = 25) who had been taking 23 mg
fluoride/day (as sodium monofluorophosphate) for an average of 4.2 years
(1.4 – 12.6 years), sister chromatid exchanges in lymphocytes were no more
frequent than in the control group (68).
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Table 2a. Results of in vitro genotoxicity studies with mammalian cells.
System Fluoride dose Effect tested Result Ref.
Hamster
  embryo cells
NaF
50-200 μg/ml
16 and 28 h
Chromosome aberrations Positive 155
Hamster
  embryo cells
NaF
20-80 μg/ml
24 h
Sister chromatid exchanges Positive 155
Hamster
  ovarian cells
NaF
1.6-1600 μg/ml
Chromosome aberrations,
sister chromatid exchanges
Positive 116
Hamster
  ovarian cells
NaF
2-40 μg/ml
24-72 h
Sister chromatid exchanges Negative 153
Human
  lymphocytes
NaF
20-40 μg/ml
2-28 h
Chromosome aberrations Positive 4
Human
  fibroblasts
NaF
20-50 μg/ml
12-24 h
Chromosome aberrations Positive 156
Human
  fibroblasts
NaF
10-20 μg/ml
24-48 h
Chromosome aberrations Positive 134
Human
  lymphocytes
NaF
4.2-42 μg/ml
2 h
Chromosome aberrations Negative 46
Human
  lymphocytes
NaF
2-80 μg/ml
48 h
Sister chromatid exchanges Negative 153
Human
  lymphocytes
NaF
4.2-420 μg/ml
48 h
Sister chromatid exchanges Negative 151
Human
  lymphocytes
KF
5.8-580 μg/ml
48 h
Sister chromatid exchanges Negative 151
Rat liver cells NaF
160 μg/ml
Increased DNA repair activity Negative 153
One study compares three groups (n = 66, 63, 70) of people who had lived for
at least 30 years in areas with three different levels of fluoride in drinking water
(0.1, 1.0 and 4.0 mg/l). The groups had different fluoride levels in urine (0.7, 1.1
and 2.8 mg/l) and blood (1.1, 1.8 and 4.0 μmol/l). A significant increase of sister
chromatid exchanges was observed in those who lived in the high-exposure area.
This group was studied further, and no difference in frequency of sister chromatid
exchange was found between persons who drank fluoride-poor water from a
spring and those who drank water with 4 mg fluoride/l. The authors concluded
that the observed difference in sister chromatid exchanges was not related to
the fluoride exposure (69).
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Table 2b. Results of in vivo genotoxicity studies with mammalian cells.
Species/system Fluoride dose Effect tested Result Ref.
Mouse oocytes NaF
16 x 250 μg s.c.
Meiotic abnormalities:
anaphase lags, bridging,
tetraploid nuclei etc.
Negative 70
Mouse oocytes NaF
35 x 5 μg/g b.w. s.c.
Meiotic abnormalities:
anaphase lags, bridging,
tetraploid nuclei etc.
Negative 70
Mouse bone
marrow cells
NaF
10-40 mg/kg i.p. or
40 mg/kg s.c. or
40 mg/kg p.o.
Chromosome aberrations Positive 121
Mouse bone
marrow cells
NaF
50 mg/l in drinking water
for at least 7 generations
Sister chromatid exchanges,
chromosome aberrations
Negative 79
Mouse bone
marrow cells
NaF
7.5-30 mg/kg i.p.
Micronucleus test Negative 60
Mouse bone
marrow cells
NaF
2 x 10-40 mg/kg i.p.
Micronucleus test Positive 121
Rat bone
marrow cells
NaF
500-1000 mg/kg p.o.
Micronucleus test Negative 4
s.c. = subcutaneous; i.p. = intraperitoneal; p.o. = per os
Another study examined the relation between fluoride content in drinking
water (0.2, 1.0 and 4.8 mg/l) and the frequency of sister chromatid exchanges
in lymphocytes. Persons in the low-exposure group had more sister chromatid
exchanges than those in the two other groups (88).
In a survey article on the genotoxicity of fluoride, the question of whether
fluoride gives rise to chromosome damage in vivo is judged to be still unanswered
(175).
Carcinogenicity
Animal data
No significant increases in tumor occurrence were observed in early animal
experiments on the carcinogenicity of fluorides (74, 148, 149), in which mice
were exposed to sodium fluoride (NaF) in either drinking water or feed. The
quality of these studies, however, was not sufficient to allow any definite
conclusions, and the studies have been criticized for methodological short-
comings, including use of small, single-sex groups, poor age matching, single
doses and brief observation periods (168). In one study (116), mice and rats were
exposed to 0, 25, 100, or 175 mg NaF/liter in drinking water for 2 years: in two
high-exposure groups of male rats there were more tumors than expected in bone
tissue (1/50, 2/50). The number was not significantly higher than controls (0/50),
but the dose-response trend was significant. No bone tumors were observed in
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female rats or mice of either sex. The authors regard a connection to floride intake
as doubtful. In another long-term study, rats were exposed to sodium fluoride in
feed: three groups of 70 rats of each sex (+ control groups) were exposed to 4, 10
or 25 mg NaF/kg b.w./day for up to 99 weeks. No increase in cancer incidence
was observed (97).
Human data
A number of epidemiological studies report elevated mortality due to various
forms of cancer, especially lung and bladder cancer but also tumors in stomach,
esophagus, pancreas, lymphatic-hematopoietic system, prostate and brain, in
workers in the aluminum industry (6, 7, 50, 51, 106, 126, 129). Since these
workers were also exposed to other substances (notably polyaromatic hydro-
carbons) and no consistent pattern has been found, it would be unwarranted
to connect the risk increase to fluoride exposure.
An elevated cancer morbidity has also been observed in the cryolite industry.
A cohort study of cryolite workers (n = 522) in Denmark compared cancer
mortality among these workers in the 1941-1989 period with mortality in the
general population. There were elevated incidences of lung and larynx cancer
(42 observed, 29.9 predicted) and bladder cancer (17 observed, 9.2 predicted).
The workers had been exposed to cryolite dust (average dust levels 30 – 40
mg/m3, estimated to be equivalent to a daily absorption of 14 – 70 mg fluoride by
an adult weighing 70 kg.) and traces of quartz. The authors mention that a large
portion of the cohort had probably been smokers. This might explain the elevation
in lung and larynx cancer, but can only partially explain the elevated bladder
cancer incidence. The results were interpreted as indicating that the elevated
incidence of bladder cancer might be due to occupational exposure to fluorides
(52).
In the United States, a population-based case-control study of fluorides and
osteosarcoma cases (n = 130, illness diagnosed before age 24) in 1978 – 1988
found no correlation between the risk of developing the illness and non-
occupational fluoride exposure (drinking water, mouthwash, toothpaste,
fluoride tablets etc.) (48).
Several epidemiological studies in various parts of the world (including
Australia, Canada, China and Taiwan, England and Wales, New Zealand,
Norway and the United States) have examined the connection between cancer
mortality and fluoride exposure via drinking water (33, 118, 139). In 1985, Knox
(76) made an assessment of existing studies and concluded that no credible
connections could be shown between cancer risk, elevated cancer mortality
and water fluoridation or naturally occurring fluoride in water. A study by
Yiamouyiannis and Burk (174) reported a correlation between drinking water
fluoridation and cancer mortality. Their study was criticized for not adjusting for
differences in age, race and sex in the compared groups, and the results have been
questioned (76). Later studies have shown no connection between cancer and
fluoride in drinking water (19, 44, 65, 95, 173).
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The International Agency for Research on Cancer (IARC) has placed fluoride
and sodium fluoride (66, 67) in Group 3: “the agent is not classifiable as to its
carcinogenicity to humans”.
Effects on reproduction
Animal data
Effects on testes and spermatogenesis have been seen in laboratory animals
exposed to fluorides. In two studies, in which rabbits were given 10 mg NaF/kg
b.w./day in diet for 18 or 29 months, structural changes in testes and sperm were
observed after 18 months. In the group that was exposed for 29 months, spermato-
genesis stopped (80, 145). Sprando et al. (143) reported that no effects on
spermatogenesis – changes in sperm count, testes volume, histopathology –
and no endocrine effects – serum testosterone, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) – could be seen in rats given drinking water
containing 25, 100, 175, or 200 mg NaF/l for 14 weeks. A similar study with the
same exposure levels gives the equivalent fluoride intakes: about 1.5, 5.6, 8.5 and
12.7 mg F/kg/day (21, 22). Nor were any effects on these parameters seen in the
first generation of young (F1 generation), exposed to these fluoride concentrations
both in utero and after birth (143). In a follow-up study, no significant histological
changes were seen in testes of F1 rats exposed to these levels of sodium fluoride
in utero and after birth (144).
In two studies of multigenerational effects and developmental toxicity of
sodium fluoride, rats were given drinking water containing 0, 25, 100, 175 or
250 mg NaFl/l (free access) for three generations (F0, F1, F2). The only effect
observed was reduced calcification of the hyoid bone in the F2 generation at
the highest dose. No effects were seen in rats with lower intake, nor were any
cumulative effects observed in the F1 or F2 generation (21, 22).
Rats were given drinking water containing 150 mg/l fluoride in the form of
sodium fluoride (free access) before and during three gestations and during the
subsequent lactation periods. Significant morphological changes were observed
in femur shafts, under both light and scanning electron microscopes. However,
no skeletal effects were observed in their pups (123, 124). No negative effects on
fetal development were seen in pregnant rats given up to 25 mg NaF/kg b.w./day
in drinking water on days 0 – 20 of gestation (20).
In a multigenerational study, female mice were given a low-fluoride diet and
drinking water containing 0, 50, 100 or 200 mg fluoride/l. Reproduction was
normal in the group given 50 mg/l, with regard to number of pups, occurrence of
infertility, time to first litter and time between litters. At higher doses, however,
growth inhibition, reduced reproduction and high mortality rates were observed.
In the group given 200 mg/l, 50% of the mice died within 8 weeks and no young
were produced (105).
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Human data
Fluorides can pass through the placental barrier. Serum concentration in the
mother has a direct relationship to that in the fetus (measured in umbilical blood):
the level in umbilical blood is about 75% of that in the mother (135). In the
fetuses fluoride is taken up in mineralized tissues (bones and teeth) (161).
Data on fluorides and effects on human reproduction are sparse.
An elevated occurrence of spontaneous abortions (45% overrisk) was described
in a nationwide study (14 companies) of female factory workers (n = 891) in
the semiconductor industry. In addition to glycol ethers, fluoride compounds
(hydrogen fluoride and ammonium fluoride) were identified as risk factors for
occurrence of spontaneous abortions. The authors pointed out, however, that the
observed correlation could be due to chance or to the existence of unidentified
co-varying substances (132, 147). Personal monitors in 35 semiconductor
manufacturing plants showed low exposure levels for fluorides, on average
0.001 mg/m3 (<2% of the OSHA exposure limit of 2.5 mg/m3) (170).
In two Russian studies, some effects on testosterone levels and luteinizing
and follicle-stimulating hormones were seen among men who had worked in
the cryolite industry for 10 to 25 years and who had diagnosed skeletal fluorosis
(152). In another study, menstrual irregularities and irritation in the genital area
were reported among women in the superphosphate industry (82), but since they
had been exposed to several substances these effects could hardly be ascribed to
fluoride alone.
A suspected connection between water fluoridation and increased prevalence
of Down’s syndrome (trisomy 21) was not confirmed in an American epidemio-
logical study in which the prevalences of Down’s syndrome between 1950 and
1966 in regions with and without water fluoridation were compared (113). Nor
have case-control studies been able to show a correlation between fluoride and
elevated risk of spontaneous abortions (8) or congenital heart disease (176).
Dose-effect / dose-response relationships
The effects of fluorides have been studied in both animals and humans. Table 3
(skin exposure), Table 4 (inhalation exposure) and Table 5 (oral exposure) present
the studies in which relationships between symptoms and fluoride exposure have
been examined in humans. Table 6 presents observations from animal experi-
ments.
Skin uptake can lead to severe systemic poisoning, which has been reported
after exposure to 60% hydrofluoric acid on 2.5% of the body surface (55). Fatal
cases of poisoning have been described after burns from anhydrous hydrofluoride
on 2.5% of the body surface (serum fluoride 3 mg/l) (150) and 70% hydrofluoric
acid on 8% of the body surface (57, 111).
The lowest fluoride level judged to cause irritation in the upper respiratory
passages is 0.7 – 2.4 mg HF/m3 (90). At this exposure level there is also an
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increase in the number of CD3-positive cells in the bronchial part of bronchial
lavage fluid, and at 2.5 – 5.2 mg HF/m3 there are indications of an inflammatory
reaction (91). Indications of an inflammatory reaction were also seen in nasal
lavage fluid at exposure to 3.3 – 3.9 mg/m3 HF (1 hour), and 7 of 10 subjects
reported upper airway discomfort (92). Slight burning sensations in nose and eyes
were reported at exposure to 26 mg HF/m3 for several minutes. At 50 mg HF/m3,
pronounced irritation of eyes and nose and stinging in the upper respiratory
passages were reported after a few minutes of exposure. The highest concentration
that two volunteers could endure for more than one minute, because of burning
skin and irritated eyes and respiratory passages, was 100 mg HF/m3 (94).
A slight stinging sensation in the face was reported by one person exposed to
1.2 mg HF/m3 for 15 days. When 5 persons were exposed to 2.1 – 3.9 mg HF/m3
for up to 50 days, they also developed slight irritation in eyes and nose and
reddened, flaking skin resembling mild sunburn (83, 84).
Long-term exposure may lead to osteosclerosis. Prolonged exposure (over
10 years) to about 0.48 mg fluoride/m3 for at least 50% of time at work yielded
no confirmed cases of skeletal fluorosis. No indications of hepatic, renal or
hematopoietic effects were seen (16). No cases of osteosclerosis were seen in
aluminum smelter workers with 10 to 43 years of fluoride exposure and urine
fluoride concentrations of 2.78 mg/l (pre-shift) and 7.71 mg/l (post-shift) (31).
Somewhat elevated skeletal density was found in 17 of 74 persons with an
average exposure of 2.81 mg F/m3 and an average employment time of 14.1 years
in the phosphate industry (29). Osteosclerosis appeared at a urine fluoride
concentration of about 15 mg/l in conjunction with exposure to HF for 16 years
(169). Skeletal fluorosis was associated with intake of 0.2 – 0.35 mg F/kg/day
(inhalation of cryolite dust). Workers with mild osteosclerosis had been employed
for an average 9.3 years, and those with pronounced osteosclerosis had been
employed for an average 21.1 years (127).
A study in Finland examined the relation between hip fractures and fluoride
content in drinking water. Total daily fluoride intake in the cohort was estimated
to be 0.6 – 3.7 mg/day. A significantly elevated relative risk of hip fracture was
seen in the highly exposed (3.7 mg F/day) women in the 50 – 65 age group when
they were compared with the low-exposure (0.6 mg F/day) group (81).
The relation between fluoride concentration in drinking water and various
fractures was studied in a population of Chinese villagers. A statistically elevated
risk of fractures was identified in the high-exposure group (14 mgF/day) when
these subjects were compared to groups with lower exposure (89).
No cases of osteosclerosis have been found in studies at workplaces with
fluoride concentrations below 2.5 mg/m3 (and urine fluoride below 5 mg/l).
However, the prevalence of identifiable osteosclerosis was high if the air
concentration exceeded 2.5 mg/m3 and/or urine fluoride exceeded 9 mg/l (62).
Although significant effects have not been demonstrated, WHO has concluded
that there is some increase in risk of skeletal effects with an intake (mostly in
food and drink) of over 6 mg F/day. Significant effects are seen at intake of 14 mg
F/day (168). Using a dose of 6 mg/day as a basis, and assuming 100% uptake and
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inhalation of 10 m3 air per workday and 5 workdays/week, an air level of 0.8 mg
F/m3 would yield this daily dose. If this calculation is made for a dose of 14 mg
F/day, the resulting air content would be 2.0 mg F/m3.
Gastrointestinal side-effects have been reported with therapeutic intake of 30
mg NaF/day for 3 to 12 months (27). Therapeutic intake of 60 mg NaF/day (389
μg fluoride/kg/day for a person weighing 70 kg) for a period of 5 years resulted
in no discernible hematological, hepatic or renal effects (59). Therapeutic intake
of 23 mg fluoride/day for an average of 4.2 years had no effect on examined
parameters in blood and urine samples, and yielded no increase in frequency
of sister chromatid exchanges (68).
Elevated occurrences of sister chromatid exchanges, chromosome aberrations
and micronuclei in blood lymphocytes were observed in conjunction with
exposure to hydrofluoric acid and silicon tetrafluoride at levels of 0.5 to 0.8
mg/m3. These workers were also exposed to phosphate fog, ammonia and sulfur
dioxide (100, 101). On the other hand, in a study of fluoride content in drinking
water (0.2, 1.0 or 4.8 mg/l) and frequency of sister chromatid exchanges in
lymphocytes, a higher frequency was seen among persons in the low-exposure
group (88).
No negative effects on fetal development were seen in rats given up to 25 mg
fluoride/kg b.w./day in drinking water on days 0 to 20 of gestation (20). Structural
changes in testes and sperm were observed in rabbits after intake of 10 mg NaF/kg
b.w./day for 18 or 29 months, and in the group treated for 29 months spermato-
genesis ceased (80, 145). Reduced ossification of the hyoid bone was observed in
the third generation (F2) of rats given drinking water containing 250 mg NaF/l; no
effects were reported in groups with lower intake (21, 22). At this exposure there
were no effects on spermatogenesis, no endocrine effects in F0 or F1 rats, and no
testicular changes in F1 rats (143, 144). Rats were given drinking water with 150
mg NaF/l for 10 weeks before and during 3 gestations and subsequent lactation
periods, and morphological changes were found in femur shafts. There were no
skeletal effects in their pups (123, 124). Reproduction in mice given drinking
water containing 0, 50, 100 or 200 mg fluoride/l was normal in the 50-mg group.
Higher doses caused growth inhibition, reduced reproduction and higher mortality
rates. Half the mice in the group given 200 mg/l died within 8 weeks, and no
young were produced (105).
In assessing the health effects of fluorides, background exposure must be
considered. A substantial portion of the Swedish population ingests a fairly
large amount of fluorides in food and drinking water.
Conclusions
The critical effect of long-term exposure to soluble fluorides is the effect on the
bones. Calculations from WHO data, which is based on intake in food, indicate
that skeletal effects appear at an air concentration of 0.8 to 2.0 mg F/m3 for an
8-hour workday. In an epidemiological study, no definite indications of skeletal
effects were seen with long-term exposure to 0.48 mg F/m3. The critical effect
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of acute exposure to airborne hydrogen fluoride, hydrofluoric acid and acidic
aqueous solutions of fluorides is irritation of mucous membranes. This effect
was reported at 0.7 – 2.4 mg/m3 in a study with experimental exposure to HF. The
toxicity of a fluoride is connected to its solubility: as a rule, less soluble fluorides
are less toxic. Deaths have been reported after oral intake of extremely low doses
– about 18 mg F/kg for adults, and even lower doses for children (about 4 mg
F/kg).
As with other irritating substances, a single high exposure to HF can lead to
acute (RADS) and permanent (asthma) damage to respiratory passages. Elevated
occurrences of respiratory complaints and effects on lung function, sometimes
with asthma, have been documented in several studies of aluminum-fluoride
production and aluminum smelters. Since many other substances were also
present, including oven gases, it is not possible to state with certainty the exact
role of fluoride compounds in the appearance of these health problems.
Regarding cancer and genotoxicity, information is still not sufficient to allow
assessment with acceptable certainty.
Fluoride passes through the placental barrier and can be taken up in mineralized
tissue by the fetus, but toxic effects on reproduction have not been shown at doses
relevant here.
Hydrogen fluoride is readily absorbed by the skin and can cause both local
damage to deep tissues and systemic poisoning. Fatal cases have been reported.
Table 3. Effects of accidental skin exposure to hydrogen fluoride.
Exposure Blood levels Effects (subject) Ref.
anhydrous HF, about 5 g
2.5% of skin
serum fluoride <3 mg/l
4 and 10 hours after the
accident
Severe systemic poisoning
(man, age 30)
12
anhydrous HF
2.5% of skin
serum fluoride 3 mg/l Death
(man)
150
70% hydrofluoric acid
legs, about 9-10% of skin
serum fluoride postmortem
4.17 mg/l
Death
(man, age 23)
98
70% hydrofluoric acid
face, chest, arms and legs
Death
(2 men, age 50 and 60)
15
70% hydrofluoric acid
8% of skin
serum fluoride 9.42 mg/l
4 hours after the accident
Death
(man, age 61)
111
60% hydrofluoric acid
2.5% of skin
inital serum fluoride
7.1 mg/l
Severe systemic poisoning
(man, age 38)
55
70% hydrofluoric acid
22% of skin
initial serum fluoride
6 mg/l
Severe systemic poisoning
(man, age 50)
55
70% hydrofluoric acid, 150 ml
legs, about 8% of skin
Death
(man, age 37)
57
anhydrous HF
arms, about 5% of skin
Severe systemic poisoning
(man)
11
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Table 4. Effects on humans exposed to fluorides by inhalation.
Exposure Urine concentration Subjects,
Effects
Ref.
0.2-0.6 mg HF/m3
1 hour
9 volunteers; 4 report slight upper respiratory
symptoms (p=0.06).
Slight reduction in FVC.
90
0.7-2.4 mg HF/m3
1 hour
7 volunteers; 6 report slight upper respiratory
symptoms (p=0.10).
No change in FVC.
2.5-5.2 mg HF/m3
1 hour
7 volunteers; all 7 report upper respiratory
symptoms (p=0.02) No change in FVC.
(No clear dose-response relationship for
symptoms involving eyes and lower respiratory
passages, no change in FEV1).
0.2-0.6 mg HF/m3
1 hour
No effect on bronchial lavage fluid. 91
0.7-2.4 mg HF/m3
1 hour
Higher number of CD3-positive cells in
bronchial lavage.
2.5-5.2 mg HF/m3
1 hour
Higher number of CD3-positive cells,
myeloperoxidase and interleukin-6 in bronchial
lavage (an expression of inflammatory reaction).
3-6 mg AlF3/m3
(average)
occupational
35-40 aluminum-fluoride production workers;
6 asthma cases in 1975, 7 in 1976.
136
0.4-1.0 mg AlF3/m3
(average)
occupational
35-40 workers, same plant, improved conditions.
2 new cases of asthma 1978-1982.
1.2 mg HF/m3
(0.8-1.7 mg/m3)
6 hrs/day, 5 days/wk,
15 days
1 volunteer; no noteworthy effects on respiratory
passages, slight stinging of face. No skin
reddening.
83,
84
2.1-3.9 mg HF/m3
6 hrs/day, 5 days/wk
up to 50 days
5 volunteers; slight stinging of face and eyes,
slight nasal irritation; red, flaking skin
resembling mild sunburn. No lower respiratory
symptoms.
3.3-3.9 mg HF/m3
1 hour
10 volunteers; 7 reported upper respiratory
irritation.
Nasal lavage: significant increases of
neutrophilic granulocytes, total number of cells,
TNF-α, eicosanoids, antioxidant activity.
93
26 mg HF/m3 2 men; endured for several minutes. Slight
stinging of nose and eyes.
94
50 mg HF/m3 2 men; after several minutes pronounced
irritation of eyes and nose, stinging in upper
airways.
100 mg HF/m3 2 men; highest concentration endurable longer
than 1 minute. Stinging skin within 1 minute,
irritation in eyes and airways.
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Table 4. Cont.
Exposure Urine concentration Subjects,
Effects
Ref.
≈ 0.48 mg fluoride/m3
≥50% of workshift
occupational
1.9 mg/l preshift,
2.7 mg/l postshift
Potroom workers in an aluminum smelter.
No confirmed cases of skeletal fluorosis. Slight
x-ray indications of higher bone density in a few
workers with more than 10 years’ exposure. No
indications of renal, hepatic or hematopoietic
effects.
16
<2.5 mg fluoride/m3 <5 mg fluoride/l In a review of older literature, no reported cases
of osteosclerosis at workplaces with these levels.
62
>2.5 mg fluoride/m3 >9 mg fluoride/l Risk of osteosclerosis deemed high at
workplaces with one or both these levels.
2.81 mg F/m3
occupational
average 14.1 years
74 phosphate workers; 17 had somewhat
elevated bone density.
29
hydrofluoride
occupational
16 years
≈ 15 mg F/l Osteosclerosis but no subjective symptoms. 169
occupational
10-43 years
2.78 mg F/l preshift
7.71 mg F/l postshift
Aluminum smelter workers; no osteosclerotic
changes.
31
Cryolite dust
(inhalation uptake of 0.2-
0.35 mg F/kg b.w./day
for several years)
Cryolite workers in Copenhagen; skeletal
fluorisis. Mild osteosclerosis cases averaged
9.3 years exposure, pronounced cases averaged
21.1 years.
127
0.5-0.8 mg/m3
hydrofluoric acid and
silicon tetrafluoride
occupational
40 workers in a phosphate fertilizer plant;
average frequency of sister chromatid exchanges
in circulating blood lymphocytes 50% higher
than controls. (The workers were also exposed
to phosphate fog, ammonia and sulfur dioxide.)
No consistent correlation between length of
employment and SCE.
The same workers; a further study found
increases in chromosome aberrations and
micronuclei in lymphocytes.
100,
101
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Table 5. Effects on humans of oral intake of fluorides.
Intake Urine/blood
concentration
Effects Ref.
>6 mg F/day
In studies from India and China:
Indications of higher risk of skeletal effects.
168
>14 mg F/day Clear increase in risk of skeletal effects.
fluoride in water
<0.1–2.4 mg/l;
daily fluoride intake
0.6–3.7 mg
Finnish study on hip fractures and fluoride in
drinking water: 6 exposure groups. Relative risk of
hip fracture was higher for women at 3.7 mg/day
(highest) than at 0.6 mg/day (lowest).
81
daily fluoride intake
0.73–14.13 mg
Study on bone fractures and fluoride in drinking
water of Chinese villagers: 6 exposure groups. High-
exposure group (14 mg F/day) had significantly
more fractures than a medium exposure group and
more hip fractures than a low-exposure group.
89
about 4 mg F/kg b.w. A child (age 2) died after eating fluoride tablets. 34
5 mg F/kg b.w. Calculated to be the smallest potentially toxic dose. 159
5–10 g NaF/kg b.w.
(32–64 mg F/kg b.w.)
Lethal dose for an adult weighing 70 kg (LD100). 61
about 18 mg F/kg b.w. 55 mg F/l
in urine
An accidental death (adult) in Alaska due to high
fluoride content in drinking water (150 mg F/l).
49
30 mg NaF/day
3-12 months
Treatment for osteosclerosis. Side-effects: stomach
pains, nausea, vomiting, damage to gastroduodenal
mucous membranes.
49
23 mg fluoride/day
1.4 to 12.6 years
9.7 mg F/l
in urine (avg.)
0.17 mg F/l
in blood (avg.)
Average intake for 4.2 years (average). No clinically
significant effects on studied parameters in blood or
urine samples compared to controls. No increase in
SCE.
68
60 mg NaF/day
about 5 years
Osteoporosis patients. No indication of significant
negative hematological, hepatic or renal effects.
59
fluoride in drinking
water
    fluoride in
urine       blood
mg/l        μmol/l
Comparative study of 3 groups living at least
30 years in areas with different fluoride levels
in local water.
69
0.1 mg/l 0.7 1.1 n=66
1.0 mg/l 1.1 1.8 n=63
4.0 mg/l 2.8 4.0 n=70, Significant increase in SCE. This group was
studied further, and there was no difference in SCE
between those who drank water from a fluoride-poor
spring and those who drank water with 4 mg
fluoride/l. It was concluded that the difference in
SCE was not caused by fluoride exposure.
fluoride in drinking
water
0.2 mg/l
Study of fluoride in water supply and frequency of
SCE in lymphocytes.
Elevated frequency of SCE in lymphocytes.
88
1.0 mg/l No elevation in SCE.
4.8 mg/l No elevation in SCE.
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Table 6. Effects on laboratory animals experimentally exposed to fluorides.
Exposure Species Effects Ref
In feed, NaF, 10 mg/kg/day
  18 months
Rabbit
Structural changes in testes, sperm
 80,
145
  29 months Spermatogenesis stopped
In drinking water, NaF
  14 weeks
  25 mg/l (1.5 mg F/kg b.w.)
  100 mg/l (5.6 mg F/kg b.w.)
  175 mg/l (8.5 mg F/kg b.w.)
  200 mg/l (12.7 mg F/kg b.w.)
Rat No effects on spermatogenesis, no
endocrine effects (serum testosterone,
LH, FSH) in F0 and F1
143,
144
In drinking water, NaF
F0, F1, F2 generations
  0 mg/l
  25 mg/l
  100 mg/l
  175 mg/l
  250 mg/l
Rat
No effect
No effect
No effect
No effect
Reduced ossification of hyoid bone, F2
 21,
 22
In drinking water
  ≤2.5 mg fluoride/kg b.w./day
  days 0-20 of gestation
Rat No visible effects on fetal development  20
In drinking water
  0 mg/l
  50 mg/l
  100 mg/l
  200 mg/l
Mouse Multigeneration study:
Normal reproduction
Normal reproduction
Growth inhibition, reduced reproduction,
high mortality
50% of mice died within 8 weeks
105
In drinking water, NaF
  150 mg/l
  10 weeks before, during
  3 gestations, following lactations
Rat Morphological changes in femur shafts
No effects on young
123,
124
NaF, p.o.
  36 – 98 mg F/kg b.w.
Rat LD50 160
NaF, p.o.
  44 – 58 mg F/kg b.w.
Mouse LD50 160
HF, inhalation, 5 minutes
  4142 mg/m3
Rat LC50 130
HF, inhalation, 15 minutes
  2242 mg/m3
Rat LC50 130
HF, inhalation, 30 minutes
  1700 mg/m3
Rat LC50 130
HF, inhalation, 60 minutes
  1092 mg/m3
Rat LC50 130
HF, inhalation, 15 minutes
  3608 mg/m3
Guinea
pig
LC50 130
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This Report is based primarily on a criteria document compiled at the request of
the Swedish criteria group (19) and updates a previous Consensus Report
published in 1992 (10).
Chemical and physical data
Lead is a very soft metal and occurs naturally as four isotopes: 204, 206, 207
and 208. In damp air the metal rapidly develops an oxide coating that protects it
against further oxidation. Above the melting point, however, oxidation continues,
and first lead(II) oxide and subsequently lead(II, IV) oxide are formed. Lead in
inorganic compounds usually has the oxidation number +II, but +IV can also
occur. Lead(IV) compounds are readily reduced to lead(II) compounds.
Lead in combination with acids can yield lead(II) salts. Although these salts
have notable ion-binding capacity, most lead(II) salts are only sparingly soluble.
The most important readily soluble lead(II) salts are lead(II) nitrate and lead(II)
acetate (7, 18).
Table 1. Some chemical and physical data for lead and some inorganic lead compounds.
Name Formula CAS No. Mol.
weight
Melting
point (°C)
Boiling
point
(°C)
Solubility
in water
(g/liter)
Lead 1 Pb 7439-92-1 207.2 327.5 1740 insoluble
Lead(II) acetate Pb(C2H3O2)2 301-04-2 325.3 280   – 443
Lead(II) nitrate Pb(NO3)2 10099-74-8 331.2 290*, 470*   – 377
Lead(II) chloride PbCl2 7758-95-4 278.1 501  950 9.9
Lead(II) sulfate PbSO4 7446-14-2 303.3 1000, 1170   – 0.042
Lead(II) carbonate,
  basic
2PbCO3·
Pb(OH)2
1319-46-6 775.6 400*   – insoluble
Lead(II) phosphate Pb3(PO4)2 7446-27-7 811.5 1014   – insoluble
Lead(II)
  chromate(VI)
PbCrO4 7758-97-6 323.2 844   – insoluble
Lead(II) sulfide PbS 1314-87-0 239.3 1114 1281 insoluble
Lead(II) oxide PbO 1317-36-8 223.2 888 1470 insoluble
Lead(II,IV) oxide Pb3O4 1314-41-6 685.6 500*   – insoluble
Lead(IV) dioxide PbO2 1309-60-0 239.2 290*   – insoluble
* disintegrates
1
 Conversion factors: 1 μg = 0.00483 μmol; 1 μmol = 207 μg
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Occurrence, use
In Sweden, exposure to environmental lead comes mostly from lead in food, with
lesser contributions from such sources as ambient air, water and tobacco. Lead
exposure also occurs in some work environments, notably lead smelters, brass
and bronze foundries, glassworks, battery manufacture and manufacture of PVC
products. Lead exposure also occurs in the construction business, around
demolition of plate coated with red lead, and sanding and renovation jobs
involving materials coated with lead-based paint (18, 19, and personal
communication from the Swedish Confederation of Trade Unions [LO]).
Uptake, biotransformation, excretion
Lead can be taken up by the lungs and digestive tract. Soluble lead compounds
can also be taken up by skin to some extent, but no quantification of skin uptake
can be made from existing data. Occupational exposure occurs primarily via
inhalation, although some lead at workplaces can be taken up orally. Large
particles are deposited high up in the respiratory passages, swallowed and to
some extent absorbed from the digestive tract. Average uptake from the digestive
tract of an adult has been reported to be about 15 to 20%. Roughly 40% of small
particles (particle size ≤1 μm; e.g. lead smoke) are deposited in alveoli and
absorbed there. The fraction is lower for larger particles. The absorption rate,
and thus uptake, depends on the solubility of the lead compound in question
(10, 18, 19).
After uptake, lead is found in blood – nearly all of it in the red blood cells.
About 80% of the lead in red blood cells is bound to the enzyme δ-aminolevulinic
acid dehydratase (ALAD). ALAD has three distinct isoenzyme phenotypes:
ALAD 1-1 (ALAD1), ALAD 1-2 and ALAD 2-2 (both called ALAD2). About 80%
of the Swedish population has ALAD 1-1, 19% ALAD 1-2 and 1% ALAD 2-2.
ALAD2 has a higher binding capacity for lead than ALAD1. Lead in serum/plasma
accounts for only a few percent of the total amount of lead in blood, but is
probably the most biologically available portion of blood lead. The average
content of lead in the blood of men not occupationally exposed has been gradually
declining in Sweden, and in 1999 was about 0.2 μmol/l (10th percentile about 0.1,
90th percentile about 0.4 μmol/l) (21). Concentrations in women are about 25%
lower (21). The soft tissues with the highest lead concentrations are liver and
kidneys. The half time for lead in blood and soft tissues is about 3 to 4 weeks, but
contributions from bone, where lead has a half time of years or decades, cause the
blood lead in persons with long-term exposures to drop much more slowly when
exposure decreases. Some lead passes through the blood-brain barrier. The
peripheral nervous system also accumulates lead. Lead is distributed to the
reproductive organs as well, and passes the placental barrier. Lead content in
blood of newborn babies is correlated to that in their mothers, but is somewhat
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lower. Lead is also excreted in breast milk, and nursing can be a major source of
exposure to a baby even though the concentration in breast milk is much lower
than that in the mother’s blood (18, 19).
A large proportion of absorbed lead is incorporated into bone, which contains
about 95% of the lead in the body. The accumulation pattern for skeletal lead
varies, however: persons with the ALAD2 genotypes seem to accumulate less
than persons with the ALAD1 genotype. The average amount of lead in the
bones of lead workers has been reported to be about 100 mg, and the amount in
Scandinavians without occupational exposure is reported to be about 8 – 10 mg.
Lead in bone constitutes a good measure of long-term exposure. Lead is liberated
from the bones, and this “endogenous” exposure can account for a considerable
amount of the lead in blood. Liberation of skeletal lead can continue for decades
after occupational exposure has stopped. The liberation rates for different types
of bone vary considerably. Liberation of lead from bone increases during periods
of high bone demineralization, such as during pregnancy or lactation, or after
menopause. Liberation is higher during lactation than during pregnancy. There is
large individual variation in the kinetics of lead metabolism in both soft tissues
and bone (18, 19).
Lead is eliminated from the body primarily in urine and feces. Urinary excre-
tion occurs by filtration in the glomeruli, probably followed by partial resorption
in the renal tubules. There is large individual variation in urinary lead excretion
at a given blood lead value (18).
Biological exposure measures
Biological monitoring of lead exposure has numerous advantages: it compen-
sates for variations in respiration and in the particle size and solubility of lead
compounds, it includes different exposure pathways (differences in hygiene), and
it also reflects non-occupational exposure. Blood lead – especially considering the
abundant documentation – is regarded as the most useful measure for assessing
dose-effect relationships. A single blood lead value, however, is not a good
measure of earlier exposure. Cumulative blood lead or bone lead can be a better
measure of long-term exposure. Measurement of bone lead by X-ray fluorescence
has been quite widely used in recent years, but experience is still limited. There
can also be some degree of uncertainty in the analyses, particularly at low blood
lead levels. Among other limitations with using blood lead as an exposure
measure is that there is a curvilinear correlation between blood lead levels and
uptake. At air lead concentrations lower than about 50 μg/m3, a small increase
in exposure can yield a large increase in blood lead and the correlation between
blood lead and air lead is virtually linear. At higher air lead concentrations blood
becomes saturated (especially the binding to ALAD) and the curve gradually
flattens out: i.e. the increase in blood lead is proportionally less. Plasma lead
probably has a linear relationship to uptake and effects, but experience here is
still limited (18, 19).
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There can be considerable variation in blood lead levels at the same concen-
tration of lead in air, due to individual factors (differences in previous lead
exposure, background exposure, lead metabolism, hygiene) and to differences
in particle size and solubility of lead compounds. Consequently, it is difficult to
translate a blood lead value to an air lead value, especially at the individual level.
Attempts have been made to correlate total lead uptake in the body (from food,
drink, air etc.) to blood lead levels in adults, using data from population studies
and experiments with volunteers. They have a wide range of possible interpre-
tations (18). An estimate based on this material indicates that persons with low
background exposure can reach an average blood lead level of about 1.5 μmol/l at
an air concentration of about 30 μg/m3, with inhalation of lead compounds having
small particle size (≤1 μm) and high solubility (18). Several more recent studies,
including some of battery production workers, yield about the same correlation.
Some of these studies also indicate that an air lead level of about 10 μg/m3 should
correspond to a blood lead level of around 1 μmol/l (8, 12, 19). Other data show
that improving work routines (personal hygiene) can be an effective way to reduce
blood lead levels (11).
Battery workers can be exposed to inorganic lead in the form of dust or smoke,
and the lead can occur in metallic or oxide form or as lead sulfate (11, 15, 19).
Exposure to less soluble lead compounds, which are biologically less accessible,
results in blood lead levels that are generally lower than they are in the battery
workers. In one study, a group average blood lead level of barely 1.5 μmol/l was
found in workers exposed to lead silicate in the production of lead crystal, even
when lead in air was around 200 μg/m3 (15).
Toxic effects
There is a wide variation in effects among people with the same blood lead values.
Some persons can develop lead poisoning at low blood lead levels, while others
with much higher levels show little or no effect (18). Factors that affect sensitivity
to lead include its distribution in the body and the bioavailability of lead bound in
different tissues. Genetic polymorphism for ALAD could also explain some of the
individual differences in sensitivity to lead (19).
The nervous system
Severe poisoning with symptoms involving the central nervous system
(encephalopathy) has been reported at blood lead levels around 4 μmol/l (Table
2). Individuals with no definite clinical symptoms of encephalopathy can have
subjective, non-specific symptoms (fatigue, anxiety, irritability, concentration
and memory problems, sleep disturbance), as well as poorer performances on
psychometric tests (18). Effects on the central nervous system (CNS) have been
indicated in various neuropsychological tests (tests that measure concentration,
coordination and memory as well as more complex functions) given to groups of
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workers with average blood lead values of 1.5 – 2 μmol/l, but only in some of
the tests used in each study. There are also limited data suggesting that slight CNS
symptoms can occur at about this blood lead value (group average) (19). There is
some uncertainty in interpreting these data, due in large part to the difficulty of
estimating exposures and the choice of control groups. Slight CNS effects have
been reported in children (exposed prenatally, via mother’s milk and during their
first years of life) at an average blood lead level of <0.5 μmol/l (see below under
Reproduction).
Exposure to lead can also damage the peripheral nervous system (PNS) and in
rare cases cause peripheral neuropathy with paralysis. Clinical symptoms and
indications of effects on the motor and/or sensory PNS are apparently common
at blood lead values around 3 to 3.5 μmol/l or higher (18), but slight sensory
symptoms and indications of reduced muscular strength have been reported in
exposed workers with group average blood lead values around 1.5 μmol/l.
Disturbances of nerve conduction velocities in motor and sensory nerves and
effects on perception of vibrations have been observed at an average blood lead
level of about 1.5 μmol/l. Effects on the autonomic nervous system (primarily
reduced heart rate variability) have also been reported in groups with average
blood lead levels around 1.5 μmol/l (18, 19).
Subclinical (negative) effects on balance have been reported to occur at
group average blood lead levels of about 1.5 μmol/l and higher. Effects on some
complex functions (including visual and auditory evoked potentials, EEG) and,
in one study, subclinical effects on vision (poorer contrast perception) have also
been reported in groups with average blood lead levels of about 1.5 μmol/l and
higher (19). In children, slight effects on hearing have been noted at group
average blood lead values of about 0.5 μmol/l – even lower in one study (19).
It is not clear whether current exposure or long-term exposure (months/years)
has more relevance to effects on the nervous system. Some data indicate that at
least some effects (e.g. encephalopathy, peripheral neuropathy) can be completely
or partly reversible if exposure is reduced (19).
Blood and blood-forming organs
High exposure to lead can cause anemia by inhibiting certain enzymes and thus
disrupting heme and nucleic acid metabolism as well as hemolysis. Inhibition of
the enzyme ALAD leads to metabolic blockage, with increase of δ-aminolevulinic
acid (ALA) in plasma and urine. The metabolic interaction with lead also results
in accumulation of coproporphyrin in plasma and urine, and of protoporphyrins
in red blood cells (18). Lead in plasma is considered to be more closely correlated
to ALA in plasma and urine and to coproporphyrin in urine than is lead in blood.
Disturbance of heme metabolism is more pronounced in women than in men.
Some data also suggest greater effects on heme metabolism in persons with the
ALAD1 genotype than in persons with the ALAD2 genotypes. Effects on heme
synthesis can affect the organism in ways other than causing anemia. Heme is
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a component of enzymes involved in energy metabolism in all cells. The body’s
ability to detoxify foreign substances can also be reduced. Low heme also leads
to an accumulation of ALA, which is neurotoxic and induces formation of free
radicals (18, 19).
Total inhibition of ALAD in blood cells, reduction of hemoglobin in blood, and
anemia have been observed in men with blood lead levels around 3 μmol/l and in
women and children with lower levels. Slight effects on hemoglobin concentration
and hematocrit (regarded as harmful effects) have been reported at group average
blood lead values around 2 – 2.5 μmol/l (18, 19). Some inhibition of enzymes in
red blood cells/bone marrow can occur at much lower exposures, however. In one
study (13), ALAD activity in red blood cells and ALA content in plasma, blood
and urine were reported to be significantly correlated to blood lead level in
workers with a group average blood lead level around 0.8 μmol/l. The blood level
that can result in “abnormal” changes in ALA-related parameters in 10% of a
group (benchmark dose) was calculated, and the result (based on that portion of
the group that had blood lead levels below 1.9 μmol/l ) indicated a reduction of
ALAD activity in red blood cells at 0.13 μmol/l and an increase of ALA in plasma
at 0.16 and in blood at 0.2 μmol/l (13). At somewhat higher blood lead levels,
inhibition of other enzymes, including pyrimidine-5´-nucleotidase (P5N) was
noted. Some inhibition of P5N has been reported at blood lead levels around 0.3
μmol/l. The clinical relevance of such small effects on heme synthesis and nucleic
acid metabolism, however, is not clear. Nor is it known whether similar enzyme
inhibition occurs in other tissues at similarly low lead exposures. This weak
inhibition can thus not be regarded as a critical effect (10, 18, 19).
Kidneys
Lead exposure can cause a deterioration of renal function, characterized by
glomerular and interstitial tubular changes that can result in chronic kidney
failure. These severe effects occur after high and prolonged exposure. Even with
advanced kidney damage there is only mild and non-specific proteinurea (18, 19).
The data are unclear with regard to effects on glomeruli at lower exposures.
Limited data suggest a possibility of effects on glomerular filtration rate (GFR)
in groups of workers with average blood lead levels around 2 μmol/l, though the
data are difficult to interpret (18, 19). There are also population studies indicating
a correlation at low exposure levels between blood lead and parameters such as
creatinine clearance, serum cystatin C, serum urate, blood urea nitrogen and
serum creatinine. These effects have been seen in groups with average blood
lead levels around 0.5 μmol/l – even lower in a couple of studies. The data may
indicate an effect on GFR. A problem with this interpretation is that the relation-
ship might be the reverse: i.e. reduction of the GFR for other reasons may have
given rise to the increase in blood lead (19).
In several studies, correlations between lead in blood and bone and effects on
proximal tubuli (elevated serum levels of urate and increased urinary excretion of
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low-molecular proteins and lysosomal enzymes) have been reported at low lead
exposures. These effects have been seen in occupationally exposed groups with
group average blood lead values of around 1.5 μmol/l or higher. Limited data also
suggest some slight effects of this nature in children with blood lead levels around
0.5 μmol/l. Effects on proximal tubuli due to cadmium exposure may be a
confounding factor in some of these studies, but for other studies this risk is
considered minimal (18, 19).
Lead also affects the metabolism of vitamin D and calcium, probably through
an effect on the kidneys. These effects have been observed in children at blood
lead levels around 0.75 – 1 μmol/l. Adults are apparently less sensitive (18).
It is not known whether current exposure or long-term exposure (years or
decades) is more relevant for kidney damage. Nor is it clear whether there is a
correlation between effects registered in some sensitive urine tests and later
clinical chronic kidney disease (18, 19). The health relevance of slight enzymuria,
for example, is unknown. There is some information suggesting that damage is
reversible if exposure is stopped. Some data suggest that ALAD genotype can
play some role in determining the nephrotoxic effects of lead, with greater
vulnerability in persons having the ALAD2 genotypes (19).
Heart and circulatory system
Exposures that raise the blood lead level above 5 μmol/l in adults or 3 μmol/l in
children are often associated with direct toxic effects on the heart muscles (18).
Reduced heart rate variability has been reported at average blood lead values
around 1.5 μmol/l (discussed further under Nervous system).
Lead can also cause a rise in blood pressure, which has been demonstrated in
both humans and animals. Elevated blood pressure was reported in early studies
of highly exposed workers, and in these cases was often ascribed to lead-induced
kidney damage. The picture is more ambiguous in recent studies of workers, who
have lower exposures, but there may be effects on blood pressure at group average
blood lead values around 1.5 – 2 μmol/l. Further, indications of a blood pressure
increase at even lower average blood lead levels (around 0.4 μmol/l) have been
found in many epidemiological studies of the general population. Available
information suggests that the effect of increasing blood lead on blood pressure is
relatively less at high blood lead values than at low ones. The mechanisms behind
the effect on blood pressure at low blood lead levels may not be the same as those
operating at high levels, where it is often associated with kidney damage. ALAD
genotype also seems to cause individual differences in sensitivity. However, it is
still a question of small increases in blood pressure, and a causal relationship has
not been established with certainty. High blood pressure is a known risk factor for
cardiovascular and cerebrovascular diseases. Elevated risk of cerebrovascular
disease has been indicated in some studies, especially among workers with high
exposure to lead (18, 19).
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Digestive tract
Lead affects the digestive tract and can cause both constipation and diarrhea,
nausea, loss of appetite and stomach cramps. Gastrointestinal effects occur at
high exposures, usually at blood lead levels of 3 μmol/l or higher (18).
Endocrine system
In groups with occupational exposure to lead and average blood lead levels
around 1.5 – 2 μmol/l, there are some indications of effects on the hypothalamus-
pineal-thyroid/adrenal axes. A correlation between blood lead and elevated serum
prolactin has been reported in some studies; it may be an early indication of
neurotoxicity (18, 19).
The immune system
Lead has a demonstrated immunosuppressive effect. Effects on humoral and
cellular immunity, but no indication of a strong immunotoxic effect, have been
observed in groups of lead workers with average blood lead levels around 2
μmol/l or higher. Increased susceptibility to infections has been reported in a
few studies (18, 19).
Genotoxicity
There are little data indicating that lead (except for lead chromate) can have
a direct genotoxic effect. However, there are several studies indicating DNA
damage via non-genotoxic mechanisms, with a consequent increase in cancer risk.
For example, lead can interfere with DNA repair, defense against free radicals,
and metabolism of various genotoxic substances. Lead has a clastogenic effect
and induces chromosome aberrations. Elevated occurrences of chromosome
aberrations, micronuclei and sister chromatid exchanges in peripheral lympho-
cytes have been reported in lead workers at average blood lead levels of about
1.5 – 2 μmol/l or higher. An increase of structural aberrations in chromosomes
is associated with an increase in cancer risk (18, 19).
Carcinogenicity
Animal studies have demonstrated that some lead compounds can have a
carcinogenic effect. The IARC assessment published in 1987 stated that there was
“sufficient evidence” for regarding inorganic lead compounds as carcinogenic to
animals. Existing epidemiological studies of exposed workers, however, generally
did not support this data despite the fact that exposures in many of them had
resulted in blood lead levels above 3 μmol/l. The IARC therefore concluded that,
for humans, the evidence of carcinogenicity was inadequate; the general
classification of inorganic lead and lead compounds was therefore “possibly
carcinogenic to humans” (Group 2B) (18). More recent data have provided
indications that lead is carcinogenic to humans as well, but there is still no definite
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proof. A slightly elevated risk of cancer has been noted in some newer studies,
but not in others. Factors such as choice of study group, smoking habits and other
exposures make it difficult to draw definite conclusions from this material (19).
Reproduction
Effects of lead exposure on reproduction have been investigated in numerous
animal experiments. Pre- and/or postnatal exposure of females can probably
disrupt hypothalamus-pineal-ovary-uterus function; one reported result was
disruption of the menstrual cycles of monkeys. Injection of high doses of lead
during gestation has been found to cause resorption of the embryos, low birth
weights, malformations and increased perinatal mortality. Long-term, low-level
exposure has been reported to affect development of the central nervous system
(CNS). Abnormal behavior and morphological changes in the brain have been
observed in primates at doses having no effect on the mothers. Disturbances in
heme metabolism have also been observed in the fetuses. Experimental exposure
in utero has been reported to reduce fertility of females (18), and effects on males
have also been shown. Lead exposure can disrupt endocrine functions in males
and – probably as a consequence of that, but also because of a direct toxic effect
on the testes – affect sperm. Reduced fertility and lower birth weights/survival
rates have also been documented in young of male animals exposed to lead (18).
There is less abundant information on humans, but it indicates that lead has
several types of effects on reproduction. Limited data suggest a connection
between higher blood lead and somewhat later menarche in girls. Longer “time to
pregnancy” was also reported in one study (19). Older literature contains reports
of spontaneous abortions/stillbirths in women exposed to high levels of lead. It is
not clear whether such effects can be observed at lower exposure levels, but there
are some data suggesting an effect at blood levels as low as about 0.5 μmol/l.
Available information, however, hardly indicates greater numbers of mal-
formations in the fetuses of women exposed to lead (18, 19), although some
studies have shown other effects on fetuses. These include disturbances in heme
synthesis, shorter gestation time, and lower growth and birth weights. Slight
effects on fetal heme metabolism have been observed in groups of women
with average blood lead levels of 0.5 μmol/l (18, 19). In some studies, inverse
correlations between blood lead and birth weight/length/head circumference are
reported for groups of mothers with average blood lead values of <0.5 μmol/l, and
in a few studies as low as 0.1 μmol/l, but other risk factors, under/overcontrolled
in the statistical model, may have affected these results (18, 19). Lower prenatal
growth was shown by regression analysis in a study of a group of mothers with
blood lead levels of 0.01 – 0.23 μmol/l (median 0.055) in week 36 of gestation
and 0.004 – 0.59 μmol/l (median 0.054) measured in umbilical blood (14). A lead
increase of 0.054 μmol/l in umbilical blood was associated with a reduction of
100 g in birth weight, 0.5 cm in birth length and 0.25 cm in head circumference. A
correlation between high blood lead levels in the mother during the third trimester
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and small head circumference in the child at six months of age was also seen in a
study of Mexican mothers with a group average of about 0.4 μmol/l. An elevation
of blood lead levels in the mothers (week 36 of gestation) from 0.05 to 1.7 μmol/l
was estimated to reduce head circumference at six months of age by 1.9 cm (16).
In other studies of Mexican mothers with a group average of about 0.3 μmol/l in
umbilical cord blood, biomarkers for lead (primarily bone lead) were negatively
correlated to growth parameters such as birth weight, length and head circum-
ference (5, 6).
Lower scores in various psychological tests, as well as less acute hearing, have
also been reported in children (Table 2). Slight CNS effects have been reported in
groups of children at average blood lead values (pregnant women/fetuses/infants)
of about 0.5 μmol/l, and the effects seem to be at least partially irreversible (18,
19). Some studies indicate slight CNS effects in children at blood levels lead
below 0.5 μmol/l, but there are numerous methodological problems (e.g. effects of
other risk factors under/overcontrolled in the statistical models) (18, 19). In one
study (4), a doubling of lead in umbilical blood (e.g. from 0.24 to 0.5 μmol/l) was
correlated to somewhat lower scores in a mental development test given at age 2,
whereas blood lead levels measured at ages 1 and 2 had no predictive value. This
study also reported an inverse correlation between maternal bone lead (measured
within 4 weeks after parturition) and results on the development test. In a
prospective study made in the Balkan states, blood lead levels were measured
prenatally and at six-month intervals from birth until 10 to 12 years of age. A
doubling of average lifetime values of blood lead (measured from birth onward),
e.g. from 0.14 to 0.3 μmol/l, was associated with a slight reduction in IQ at age
10 – 12. There was reported to be a stronger correlation between IQ and skeletal
lead in these children (20). In a meta-analysis based on 8 different studies, it was
concluded that an increase of average blood lead from 0.5 to 1 μmol/l yielded a
2.6 point reduction in IQ (17). Children whose blood lead levels never rose above
0.5 μmol/l during this monitoring period had at 10 years of age IQ values that
were inversely correlated to blood lead values at age 2. It was also reported that
an inverse correlation existed at blood lead levels below 0.24 μmol/l and that no
threshold value could be established (1, 2). In another study, there was a strong
and significant inverse correlation between blood lead and IQ at ages 3 and 5 in
children who in repeated measurements had never had blood lead levels above
0.5 μmol/l. Using a non-linear model, it was calculated that an increase in blood
lead from 0.05 to 0.5 μmol/l would decrease IQ by 7.4 points. The calculated
reduction of IQ was lower for the same blood lead increase when initial levels
were higher (3). IQ reductions proportionally greater at low blood lead levels than
at high ones have also been reported in other studies (3). Lead exposure, however,
explains only a few percent of the variation in IQ (9).
There are also some data on lead-exposed men. A correlation between lead
content in sperm and in blood has been reported in lead workers. There are
also indications that occupational exposure to lead has some effects on the
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hypothalamus-pineal-testes axis, sperm quality and possibly male fertility in
groups of workers with average blood lead values of 1.5 – 2 μmol/l and above.
Other effects reported in some studies of lead-exposed men are reduced libido,
elevated risk of miscarriage in their wives, and reduced birth weights in their
children. Selection and other factors make it extremely difficult to interpret
these studies, however (18, 19).
Dose-effect / dose-response relationships
Limited and uncertain data indicate negative effects on prenatal growth at average
blood lead values (mothers/fetuses) as low as 0.1 μmol/l, i.e. at levels found in the
Swedish populace, and lower than those found in Swedish lead workers. Effects
on the central nervous systems of children have been reported at blood lead levels
below 0.5 μmol/l. It is not known whether the CNS effects at such low blood lead
levels are due primarily to the mother’s exposure before the child was born or to
the child’s postnatal exposure. It should be noted that lead accumulates in bone
and is liberated during pregnancy and lactation, so the mother’s lead exposure
earlier in life also affects the risk.
Effects on blood pressure have been reported in large epidemiological studies
of the general population, with a marginal increase at average blood lead levels
as low as about 0.4 μmol/l. Such an increase in blood pressure may imply some
increase in risk for strokes and heart disease. Some data from population studies
may also indicate an effect on kidneys at average blood levels of about 0.5 μmol/l,
although these data are difficult to interpret. More definite data indicate that slight
effects on kidneys can appear in occupationally exposed persons at group blood
lead averages of about 1.5 μmol/l. Effects on the nervous system and endocrine
system have been reported at the same average blood lead levels, and effects on
hemoglobin concentration, immune system and sperm quality are reported at
about 2 μmol/l. Some data also suggest increased DNA damage at group blood
lead averages around 1.5 – 2 μmol/l. Correlations between blood lead levels and
effects observed in humans are shown in Table 2.
Conclusions in most of the studies are based on differences between groups
with different exposures (average values/median values), which makes it difficult
to identify a “no observed adverse effects level” (NOAEL) or a “lowest observed
adverse effect level” (LOAEL). Methodological problems such as lack of
sensitivity in the effect measurements and inadequate control of other risk factors
can also occur, particularly with low blood lead levels. Add to this the wide
variation in sensitivity to lead (due partly to genetic predisposition) and our
relative ignorance regarding the reversibility of some effects. In some cases it
is difficult to judge whether subtle, sub-clinical effects, identified with sensitive
methods, constitute a genuine risk to a person’s health (and thus are relevant
here). The relationship between earlier exposures or exposure peaks and the
appearance of harmful effects is also difficult to assess (18, 19).
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Blood lead is not an ideal measure of exposure, although it is still regarded as
the most useful for assessing dose-effect relationships – mostly because of the
abundant documentation. A single blood lead value is a poor measure of earlier
exposure. Cumulative blood lead or bone lead may be a better measure of long-
term exposure. Other limitations on using blood lead as an exposure measure
include the fact that blood becomes saturated at higher exposure levels and that,
particularly at very low levels, analysis methods may have a high margin of error.
Biological monitoring of lead exposure, however, has many advantages over air
monitoring. It compensates for variations in respiration and in particle size and
solubility of the particulate lead compounds, it covers all paths of uptake, and it
also reflects non-occupational exposure. At a given air lead concentration, blood
lead levels can vary with lead compound (solubility), particle size and individual
physiological factors. It is thus difficult to translate a blood lead value to an air
lead value (18, 19).
Conclusions
The critical effects of occupational exposure to lead are judged to be its effects on
fetuses and breast-fed babies. There are several studies reporting inhibited growth
and effects on the central nervous system in groups of children with average blood
lead values (pregnant women/fetuses/babies) in the range 0.1 – 0.5 μmol/l. It is
not clear, however, whether the effects on the central nervous system are due
primarily to the mother’s exposure. It should be remembered that lead accumu-
lates in bone and is liberated during pregnancy and lactation, meaning that the
lead exposure of the mother earlier in life is also relevant to the risk. In the
Swedish population blood lead levels are about 0.2 μmol/l for men and about
0.15 μmol/l for women. Effects in fetuses and breast-fed babies may exist around
these levels.
Effects on blood pressure are reported in large population studies, with a
marginal increase at average blood lead levels of about 0.4 μmol/l. An increase of
this nature may mean some increase in risk of stroke and heart disease. Effects on
kidneys, nervous system and endocrine systems, as well as DNA damage, have
been reported in occupationally exposed groups with average blood lead levels
of 1.5 μmol/l. Effects on hemoglobin concentration, immune system and sperm
quality have been reported in groups with average blood lead values around 2
μmol/l. Lead is carcinogenic to experimental animals, but there is only limited
evidence that it is carcinogenic to humans.
There is no simple relationship between levels of lead in air and in blood, and
it is therefore not possible to give an air lead concentration for the critical effects.
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Table 2. Dose-effect relationships (LOEL – lowest observed effect levels) between
lead in blood (averages in the studied populations) and effects on humans (19).
 General populationOrgan Effects Occupationally
    exposed
   (μmol/l)1 Adults(μmol/l)1
Children
(μmol/l)1
Nervous system
   Central Encephalopathy >4.0 >4.0 >4.0
Slight symptoms 1.5 - 2.0 - -
Neuropsychological 1.5 - 2.0 - <0.52
   Peripheral Symptoms 1.5 - -
Neurophysiological 1.5 - -
   Complex effects Cerebral reaction potential 1.5 - -
Balance 1.5 - -
Hearing - - 0.5
   Autonomic Heart rate variability 1.5 - -
Blood Anemia >3.0 >3.0 >3.0
Hemoglobin concentration 2.0 - 2.5 - -
Heme metabolism 0.1 - 0.3 - -
Nucleotide metabolism 0.3 - -
Kidneys Tubular 1.5 - 0.5 ?
Glomerular 2.0 ? 0.5 ? 0.5 ?
Cardiovascular Blood pressure 1.5 - 2.0 ? 0.4 1.8 ?
Heart rate variability 1.5 - -
Endocrine system3 Hypothalamus/pineal/
thyroid/adrenal axes
1.5 - 2.0 - -
Immune system Immune suppression 2.0 - -
Mutagenicity Chromosome aberrations,
 SCE, micronuclei
1.5 - 2 - -
Reproduction
   Women Miscarriage ?4 0.5 ? -
Fetal growth - 0.1 ? -
Neuropsychological effects - - <0.52
   Men Endocrine function 1.5 - -
Sperm quality 2.0 - -
Fertility 2.0 ? - -
Digestive system Constipation, stomach
cramps
>3.0 >3.0 >3.0
?  = Limited data, inconsistent results and/or possible/probable confounding factors
– = Not relevant or not sufficiently studied
1
 The interval represents several different studies
2
 Uncertain whether the effects are primarily due to pre- or postnatal exposure
3
 Not including reproduction
4
 Levels not identified, probably high
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Consensus Report for Xylenes
September 14, 2005
This Report is based primarily on a document from the IPCS (42) and on articles
published prior to 2005. The Criteria Group published an earlier Consensus
Report for xylene in 1981 (50).
Chemical and physical data
o-xylene m-xylene p-xylene
CAS No.: 95-47-6 108-38-3 106-42-3
Synonyms: 1,2-dimethylbenzene 1,3-dimethylbenzene 1,4-dimethylbenzene
o-methyltoluene m-methyltoluene p-methyltoluene
1,2-xylene 1,3-xylene 1,4-xylene
o-xylol m-xylol p-xylol
ortho-xylene meta-xylene para-xylene
Structure:
Formula: C8H10 C8H10 C8H10
Molecular weight: 106.16 106.16 106.16
Density: 0.876 0.860 0.857
   (g/cm3, 25 °C)
Boiling point: 144.4 139.1 138.3
   (°C, 101.3 kPa)
Melting point: -25.2 -47.9 13.3
   (°C, 101.3 kPa)
Vapor pressure: 0.66 0.79 0.86
   (kPa at 20 °C)
Distribution coefficients:
   Poil/air 4360 3842 3694
   Pblood/air 31 26 38
   Polive oil/blood 140 146 98
   Poctanol/water 3.12 3.20 3.15
Solubility in water: 142 146 185
   (mg/l)
Conversion factors: 1 ppm = 4.35 mg/m3; 1 mg/m3 = 0.23 ppm
   (25 °C, 101.3 kPa)
CH3
CH3
CH3
CH3
CH3
CH3
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Xylene is an aromatic hydrocarbon. At room temperature it is a clear, flammable
liquid with a pleasant odor. The odor threshold for xylene in air is about 1 ppm
(4.35 mg/m3) (42). Xylene occurs in three isomeric forms: ortho-, meta-, and
para-xylene. All three isomers are soluble in organic solvents such as ethanol,
diethylether, acetone and benzene. Industrial grade xylene is 40 – 60% m-xylene,
with ethylbenzene, o-xylene and p-xylene each accounting for a further 10 – 20%.
Xylene is distilled primarily from petroleum and to a lesser extent from coal.
About 92% of mixed xylenes is used in gasoline. The p-xylene isomer is used in
production of dimethyl terephthalate film and phthalic acid diisooctyl ester for
production of polyester fibers and films. Most o-xylene goes into production of
phthalic acid anhydride, which is used to make phthalate plastic, and m-xylene
is used in production of isophthalic acid for making polyester plastic. Industrial
(mixed) xylene is used mostly as a solvent in production of paints, pesticides,
pharmaceuticals, rubber and plastic, and in the perfume and leather industries
(42).
Workers in the chemical and paint industries and workers who use products
containing xylenes (e.g. painters, printers) can be occupationally exposed, but
occupational exposure to xylene alone is rare. Exposure levels in histology
laboratories can range from 20 to 70 ppm (90 – 300 mg/m3) (80). Exposure is
usually mixed, however: other organic solvents such as toluene, ethylbenzene, n-
hexane and isopropanol are often present as well. A typical exposure level for one
workshift in various kinds of painting shops is below 5 ppm (20 mg/m3). Around
printing presses and in chemical plants there may be brief exposures of up to 100
– 200 ppm (400 – 900 mg/m3) (9, 42, 89), and around installation of flooring
concentrations up to 7000 ppm (30,000 mg/m3) may occur (62).
Uptake, biotransformation, excretion
The primary exposure route for xylenes is inhalation of xylene vapors. When
volunteers were exposed to different xylene isomers in concentrations up to 200
ppm (870 mg/m3), relative uptake was reported to be 59 – 64% (75, 84). Since the
relative uptake is independent of physical activity, the absolute uptake increases
in proportion to the increase in workload and pulmonary ventilation (75). Blood
levels also increase with workload. After two hours of exposure to 50 ppm (217
mg/m3) m-xylene with a workload of 50 W, the maximum concentration in blood
was 11.2 μmol/l (about 1.2 mg/kg) (24). After 30 minutes of exposure to 200 ppm
(870 mg/m3) xylene (mixed) while resting, blood level was 1.6 mg/kg (about 15
μmol/l) (98). In this study, blood level rose to 7 mg/kg (about 66 μmol/l) with 90
minutes of exposure to 200 ppm and a 50 W workload.
Skin uptake of liquid xylene was quantified by having subjects immerse their
hands in liquid m-xylene for either 15 or 20 minutes. Absorption, calculated from
the amount of m-methylhippuric acid excreted in urine, was 2 – 2.5 μg/cm2/minute
(54, 72). If the ECETOC criteria for skin notation are applied (16), i.e. exposure
of 2,000 cm2 skin for 1 hour, the dose absorbed through the skin would be 240 –
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300 mg, equivalent to 24 – 30% of the dose absorbed by inhalation at 200 mg/m3
(the present Swedish exposure limit), assuming inhalation of 10 m3 of air during
an 8-hour shift and uptake of 50%. Skin exposure to liquid xylene can thus result
in significant absorption.
Skin uptake of xylene in vapor form was studied in 5 men who were exposed to
300 or 600 ppm (1305 or 2610 mg/m3) xylene for 3.5 hours. Total absorption of
m-xylene was about the same as with inhalation exposure to about 10 ppm (44
mg/m3) for the same amount of time (74). This indicates that with whole-body
exposure the dermal contribution to total uptake would be about 1.7 – 3.3% of the
inhaled dose. In one study (56), the contribution of dermal uptake, estimated with
use of a physiologically based pharmacokinetic model, was 1.8%. In a later study
of dermal uptake, the contribution of xylene in vapor form was calculated to be
0.2% (47). These calculations were based on a reference inhalation exposure of 30
minutes at 19 mg/m3 (4 ppm) and exposure of the lower arm and hand to m-xylene
for 20, 45, 120 or 180 minutes (six men). The xylene concentration was measured
in exhaled air.
All the xylene isomers are absorbed when administered orally to rats. The
maximum concentration in blood was reached 4 hours after single doses (by
gavage) of 0.5 – 4 g m-xylene or 1.1 g p-xylene/kg body weight (42).
Xylene is distributed rapidly to body organs by the blood. For organs with rich
blood flow it takes only a few minutes to reach equilibrium, whereas it takes some
hours for muscle tissue and several days for fat (76). Xylene has high affinity for
adipose tissue. The measured half time for xylene in human subcutaneous fat was
about 58 hours (20). After 5 to 6 days of repeated exposure to 90 – 200 ppm (413
– 870 mg/m3) xylene, about 3.7 – 8.0% of the total lung uptake was found in
adipose tissue (20, 75).
Xylene has been shown to pass the placental barrier in both humans and
laboratory rodents (14, 29, 65, 92).
Autoradiography of male mice that had inhaled 14C-labeled xylene showed an
accumulation of non-volatile metabolites, primarily methylhippuric acid, in the
olfactory bulb (30). The accumulation of methylhippuric acid in the olfactory bulb
may indicate transport from nasal mucosa to the olfactory bulb, but it might also
be explained by blood transport.
About 95% of the xylene that is absorbed by humans is excreted as metabolites
in urine, and only a little is eliminated unchanged in exhaled air (73). The
clearance of p-xylene from the blood has been calculated to be 2.6 liters/kg/hour
at 20 ppm (87 mg/m3) and 1.6 liters/kg/hour at 70 ppm (304 mg/m3) – on the same
order of magnitude as hepatic blood flow, which indicates high metabolic capacity
(94).
The main biotransformation pathways for xylene are summarized in Figure 1.
Xylene is transformed primarily to methylbenzoic acid via microsomal side-chain
oxidation. This is followed by binding to glycine, forming methylhippuric acids
which are excreted in urine. In humans, the glycine conjugation can be saturated
at high xylene concentrations: this has been calculated to occur at 270 ppm
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Figure 1. Metabolism of m-xylene (modified from Reference 73).
(1174 mg/m3) with moderate physical labor and at 780 ppm (3393 mg/m3) during
rest (71). Aromatic oxidation of xylenes to dimethylphenols (Figure 1) accounts
for only 1 – 3% of total metabolism (22, 73). Small amounts of glucuronide esters
of methylbenzoic acid and trace amounts of methylbenzyl alcohol have been
identified in human urine (6, 22, 68).
Most of the studies of xylene metabolism have been made with rats. In rats,
as in humans, the primary metabolic pathway is oxidation of one of the methyl
groups (18). Unique to rats, however, is that a relatively larger proportion of the
xylene is metabolized to methylmercapturic acid, a few percent after exposure to
m- and p-xylene and 10 – 20% after exposure to o-xylene (95, 96). It is possible
that xylenols and their reactive intermediates are formed via aromatic oxidation,
but if so the amounts are extremely small (45).
Two excretion phases, with half times of 3.6 and 30 hours, have been identified
for methylhippuric acid in urine of occupationally exposed subjects (19).
In a study in which volunteers inhaled 50 ppm m-xylene, there were no observ-
able sex differences in uptake, biotransformation or excretion of xylene (24).
Biological measures of exposure
Methylhippuric acid in urine is commonly used as a biomarker for xylene
exposure. The analyses are usually made with liquid chromatography and UV
detection. Methylhippuric acid is not found in unexposed people. Excretion of
methylhippuric acid is proportional to exposure levels at both low (<15 ppm) (44)
and higher (up to about 100 ppm) (38) xylene levels. It is stated in a review article
that 8 hours of exposure to 100 ppm (435 mg/m3) corresponds to 1.5 – 2 g
methylhippuric acid/g creatinine in urine samples taken after a workshift (53).
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This figure is an average from several studies. Measurements of xylene in blood,
urine and exhaled air are also reliable indicators of xylene exposure (8, 86). These
analyses are usually made with gas chromatography.
Germany has a legally binding biological exposure limit (BAT: Biologischer
Arbeitsstoff-Toleranz-Wert) of 2000 mg/l for methylhippuric acid in urine after a
workshift, and the ACGIH in the U.S. recommends a biological limit (BEI:
Biological Exposure Index) of 1.5 g/g creatinine after a workshift.
Toxic effects
Human data
Neurological and psychological changes have been observed in workers exposed
to solvent mixtures containing xylene (42). Common acute symptoms are head-
ache, fatigue, dizziness and intoxication. Long-term and/or heavy exposures can
lead to severe brain damage, often referred to as psychoorganic syndrome (POS)
or chronic toxic encephalopathy, which is characterized by deterioration of
memory, concentration and learning ability, and emotional symptoms such as
fatigue and depression (52, 61, 69). This type of damage has commonly been
associated with exposure to solvent mixtures. Since there is usually no quanti-
tative information on exposures, it is impossible to describe a dose-response
relationship.
From a study population of 994 workers exposed to solvents, 175 workers were
chosen on the basis of whole-day measurements (personal monitors) showing
exposure to a solvent mixture containing ≥70% xylene. These workers had been
exposed for an average of 7 years. The xylene concentration was 14 ppm
(geometric mean; 21 ppm arithmetic mean), with individual values up to 175 ppm
(8-hour time-weighted averages). An elevated prevalence of symptoms was found
in the exposed workers when they were compared with the control group (n = 241
unexposed workers). The symptoms comprised CNS effects (nausea, anxiety,
forgetfulness, loss of concentration) and irritation of eyes, nose and throat. There
was no observed effect on the number of white blood cells or on liver and kidneys
(89). In the same study population there were 233 workers exposed to a mixture of
4 ppm xylene (individual values up to 103 ppm) and 3 ppm toluene (maximum
value 203 ppm) (geometric means, 8-hour time-weighted averages). The pre-
valence of CNS symptoms in this group was higher than in the controls (n = 241)
(9). These two studies are difficult to evaluate because of shortcomings in design,
including the formulation of the questionnaire and the fact that only a few
symptoms showed the anticipated dose-response relationship.
EEGs were used to study “event-related potentials” in laboratory personnel
exposed to xylene and formaldehyde. There was a correlation between m-
methylhippuric acid in urine and latency time (55). This study is not described in
sufficient detail to allow any definite conclusions. For example, it is impossible
to determine whether the subjects were still being exposed during the EEG
recording. Exposure to formalin may also have played some role.
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In a report on 38 occupationally exposed workers with acute xylene poisoning,
CNS effects (headache, nausea, dizziness), gastrointestinal symptoms (nausea,
vomiting), liver and kidney damage, and irritation of eyes, nose and throat were
common symptoms (5). Headache, dizziness and nausea were observed after
exposure to about 700 ppm (3031 mg/m3) xylene. Exposure lasting about 1 hour
occurred in a hospital laboratory where 1 liter of xylene was poured into a sink.
Symptoms were reported by 9 of 15 exposed workers, and lasted from 2 to 48
hours (48).
About 20 studies with experimental exposure to o-, m-, p-xylene or to xylene
mixtures have been made with human volunteers. Most of them were made at
the Institute of Occupational Health in Helsinki. In brief, these studies show that
temporary CNS effects appear after a few hours of exposure to about 100 ppm. At
this level, effects on reaction time, coordination, memory and balance were seen
in several of the studies (15, 82, 83). Savolainen et al. (82) compared effects of
constant and fluctuating xylene concentrations in a small group of volunteers (n =
6) exposed 6 hours/day for two weeks. The effects were more pronounced at the
beginning of the exposure and with fluctuating exposure than they were with
constant exposure having the same time-weighted average (100 ppm). In another
study (83), eight volunteers were monitored during six days of exposure either to
a constant 90 ppm (392 mg/m3) or to concentrations fluctuating between 64 ppm
(278 mg/m3) and 200 ppm (870 mg/m3) with a time-weighted average of 92 ppm
(400 mg/m3). They did light physical work daily, 4 x 10 minutes with a 100-W
load on a bicycle ergometer. There were observable effects on balance, coordi-
nation and reaction time at the constant exposure. In another study with 10
volunteers, it was found that four hours of exposure to 100 ppm (435 mg/m3)
xylene (undefined composition) resulted in lower performances on a memory
test and two different tests of reaction time (15).
Sixteen men were exposed to 70 ppm (304 mg/m3) p-xylene for 4 hours: no
effect on performance in psychological tests and no irritation of eyes, nose or
throat was reported after the exposure (1).
In an exposure chamber study, 56 healthy volunteers (28 women and 28 men)
were exposed for 2 hours, on two occasions, to either 50 ppm m-xylene or pure
air. Before, during and after the exposures they rated their discomfort levels on a
questionnaire (Visual Analog Scale). Symptoms that were rated were discomfort
in the eyes, nose, throat or airways, breathing difficulty, solvent smell, headache,
fatigue, nausea, dizziness and feeling of intoxication. All symptoms increased
significantly with the xylene exposure (p≤0.05, Wilcoxon signed rank test) at
some time (after either 60 or 118 minutes of exposure) in one or both sexes.
The differences in symptom ratings before and during the exposure were small,
however (3 – 12 mm, or “hardly at all” to “somewhat”) except for solvent smell
(34 – 45 mm, “somewhat” to “rather”). Sex difference was significant only in
ratings of discomfort in throat and airways. Other effects measured in this study
were lung function, blinking frequency, nasal swelling, color vision and inflam-
matory markers in nasal lavage fluid. In these measures, no effect of the xylene
exposure was seen (23).
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A study from 1943 reports irritation of eyes, nose and throat in 10 persons after
they were exposed to 200 ppm xylene (composition not given) for 3 to 5 minutes
(66).
Four of six persons reported eye irritation after 15 minutes of exposure to 460
or 690 ppm (2000 or 3000 mg/m3) of a solvent mixture containing 7.6% o-, 65%
m-, 7.8% p-xylene and 19.3% ethylbenzene. One of the six reported eye irritation
at 230 ppm (1000 mg/m3), and no irritation was reported at 110 ppm (500 mg/m3)
(7).
Volunteers who immersed their hands in liquid xylene reported burning and
stinging sensations, and their hands became red (erythema) within 10 minutes.
The symptoms disappeared within 10 to 60 minutes after they removed their
hands (21, 54, 72). One case of contact urticaria due to xylene exposure has
been reported (97).
Effects on liver have been reported in workers exposed to xylene, but
these studies contain no quantitative exposure data. In one case report, a
42-year-old painter exposed mostly to xylene had elevated ASAT (aspartate
aminotransferase) and ALAT (alanin-aminotransferase) levels in serum and
normal γ-GT (γ-glutamyl transferase). He had low alcohol consumption, but a
biopsy revealed fatty changes in his liver (17). Fifteen workers in the chemical
industry and 8 painters had changes shown by liver tests after several years of
exposure to solvents. The liver test results were normalized within three to six
weeks after exposure was stopped (85). Of 156 patients (house painters) examined
for solvent damage, 23 had elevated aminotransferases in serum. Histologic
examination of their livers revealed fatty degeneration in 11 of them, and in six of
these focal necroses were also seen (13). Of 25 workers in the chemical industry
who had been exposed to toluene, xylene, methylethylketone and other solvents,
13 had elevated levels of liver enzymes, γ-GT, serum ASAT and ALP (alkaline
phosphatase) (25). Indications that liver damage is more common in house
painters than in carpenters were observed in one study (58), whereas another study
of 47 workers exposed to 19 ppm (82 mg/m3 median) xylene showed no effects on
liver enzymes in comparisons with unexposed workers (57). Nor was any effect
on liver enzymes observed in a study in which painters with an average exposure
of 6 ppm xylene (26 mg/m3) were examined (51).
There is a case-control study of 30 cases (20 to 59 years old) of cirrhosis
(diagnosed by biopsy) and 120 randomly chosen controls from the same
geographical area. Exposure estimates were based on a questionnaire including
job title and solvent exposure (solvent undefined) at work. The result for those
who had been moderately exposed for more than 1 year in the most recent 15
years showed an age-adjusted Mantel-Haenszel odds ratio of 4.3 (95% CI: 1.2 –
15). For those with high exposure the odds ratio was 7.7 (95% CI: 1.7 – 48),
which indicates that occupational exposure to solvents may cause fatty liver
disease (59).
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Animal data
Xylene has low acute toxicity with both inhalation and oral administration.
For mice and rats, the LC50 for inhalation ranges from 4300 to 6000 ppm and the
LD50 for oral administration ranges from 3.6 to 5.6 g/kg for the different xylene
isomers. A dermal LD50 of 12 g/kg has been reported for rabbits (42).
For mice exposed to 500 – 4000 ppm (2200 – 17,000 mg/m3) m-xylene, the
RD50 (the concentration that reduces respiratory rate by 50%) was determined
to be 1360 ppm (5900 mg/m3) (49).
Groups of Mongolian gerbils (4 males and 4 females/group) were continuously
exposed to 0, 160 or 320 ppm xylene (18% o-, 70% m-, 12% p-xylene, <3%
ethylbenzene, <0.1% toluene) for three months. Four months later, the
concentrations of two markers for astroglial cells (GFA and S-100) and DNA
were measured in various parts of the brain. In the group exposed to 320 ppm the
levels of GFA and S-100 were significantly higher in the frontal cerebral cortex
and GFA was higher in the cerebellar vermis, compared with controls. In the
anterior part of the vermis the GFA level was significantly higher with the 160
ppm exposure as well. In the posterior part of the cerebellar vermis the DNA
concentration was significantly higher than controls after exposure to both 160
and 320 ppm. According to the authors, these results indicate that xylene induces
an increase of astroglial cells in certain parts of the brain as an indication of brain
damage, and that the damage is irreversible (79).
Male rats (n = 11) were exposed to 100 ppm m-xylene 6 hours/day, 5 days/week
for 4 weeks. Behavior tests were administered 20 to 60 days after the exposure.
Compared with unexposed controls (n = 10), the exposed group showed changed
behavior in a “passive avoidance test” (given 39 – 48 days after the exposure),
a “hot-plate test” (given 50-51 days after the exposure) and “active avoidance
learning (acquisition)” (day 54 after the exposure). According to the authors, these
results show that short-term exposure to 100 ppm m-xylene yields permanent
changes in the behavior of rats. Xylene induced the same behavioral changes as
trimethylbenzenes (TMB) (32). The authors suggest that, if xylene and TMB
affect the dopaminergic system in the same way as toluene has been shown to do,
this might explain the observed changes in behavior. A possible explanation for
the effects on behavior may be that xylene induces a stress reaction in the rats.
Many solvents, including xylene, have been shown to induce EEG changes similar
to those induced by the odor of rat predators such as foxes or weasels. This
hypothesis is also compatible with an effect on the dopaminergic system
associated with stress reactions (32).
A single application of xylene (unspecified) was slightly irritating to the skin of
rabbits and guinea pigs (37). Application of 0.5 ml p-xylene to the skin of rabbits
for 4 hours under occlusion was judged to meet the EEC criteria for skin irritation
(43). Xylene caused erythema and increased capillary permeability in rat skin, a
result of liberated histamine and 5-hydroxytryptamine (10). No published data on
skin sensitization were found.
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Application of 0.05 – 0.5 ml liquid xylene (individual isomers or unspecified
mixture) to the eyes of rabbits caused immediate discomfort and spasms in the
eyelids, followed by slight irritation of the conjunctiva and slight, temporary
corneal necrosis (37). Application of 0.1 ml xylene (unspecified) in rabbit eyes
caused slight irritation (46).
In one study, 250 μl m-xylene was applied to the backs of rats under occlusion
for 1 hour. Skin biopsies taken before and 1, 2, 4 and 6 hours after the beginning
of exposure showed increased interleukin-1α (maxima after 1 and 2 hours) and
inducible nitric oxide synthase (maximum after 4 hours). According to the authors
these markers may reflect the skin-irritating ability of xylene. Histological
changes 6 hours after the application (blister formation and granulocyte
infiltration) were also observed in the study (33).
Hearing loss in rats exposed to xylene has been demonstrated in several
studies (11, 26, 67, 70). In one study the effect was shown after exposure to 800
ppm mixed xylene 14 hours/day, 7 days/week for 6 weeks (70). In another study
(67), a slight loss of hearing was demonstrated after exposure to 1000 ppm mixed
xylene 18 hours/day for 61 days. In a study by Gagnaire et al. (26), only p-xylene
(6 hours/day, 6 days/week for 13 weeks) yielded hearing loss at 900 ppm (“brain-
stem auditory evoked response” was tested). The effect was not seen at 450 ppm
p-xylene (26). Crofton et al. (11) showed that rats exposed to a mixture of xylene
isomers, 1800 ppm, 8 hours/day for 5 days, developed hearing loss in the
medium-frequency range (8 –16 kHz). This pattern is similar to the one shown
by toluene (11).
All three xylene isomers affect the oculomotor nerve, which controls eye
movement, after i.v. administration to rats. The threshold in blood for the effect
was 1.6 – 1.9 mmol/l (88). Nystagmus has also been reported in rabbits exposed to
m-xylene. The effect on the nerve was observed at blood concentrations above 0.3
mmol/l (3). Humans would reach this blood concentration with light work (50 W)
at an air concentration of about 1000 ppm (4350 mg/m3) (see Biological measures
of exposure).
Enlarged livers and increased activity of liver enzymes (ASAT, ALAT,
ornithine carbamyl transferase) and cytochrome P450 after inhalation exposure
to relatively high concentrations of xylene (>1000 ppm, 4 hours/day) have been
observed in several studies. Slight changes in hepatocytes and some effect on
liberation of catecholamines in the brain have also been observed (42).
Benzene has been shown to induce toxic effects in bone marrow. In compara-
tive studies with benzene, xylene yielded no indications of bone marrow toxicity
(73).
Mutagenicity
None of the xylene isomers was mutagenic to Salmonella typhimurium. The
xylene isomers induced no DNA-mediated toxicity in several strains of bacteria,
either with or without addition of metabolic systems (42). Exposure to industrial
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xylene, but not exposure to m- or o-xylene, yielded recessive lethal mutations in
Drosophila (12). In the same study, it was found that exposing rats to 300 ppm
(1300 mg/m3) 6 hours/day, 5 days/week for 9, 14 or 18 weeks did not induce
chromosomal aberrations in bone marrow. Xylene (unspecified) induced no sister
chromatid exchanges or chromosome aberrations in human lymphocytes in vitro
(28). Nor did any of the xylene isomers induce micronuclei in the bone marrow
of mice after two intraperitoneal doses (105 – 650 mg/kg b.w.) (64).
Carcinogenicity
Human data
Epidemiological studies have yielded no convincing evidence of an elevated risk
of cancer after exposure to xylenes. Gerin et al. made a case-control study in
Montreal (27) in which 3730 cancer patients and 533 controls were interviewed
about occupational exposures (benzene, toluene, xylene and styrene). There were
15 types of cancer cases (not leukemia). Exposure levels were low and there were
high correlations between benzene, toluene, xylene and styrene. For most of the
cancer types, these substances showed no increase in risk. A somewhat higher OR
(5.8, 95% CI: 1.5 – 22.0) was found for xylene and colon cancer. In another study
(31), probably of the same material, only occupational exposure and risk of colon
cancer was investigated: the risk after exposure to xylene was not significantly
elevated (OR 1.9, 95% CI: 0.8 – 4.3).
A study by Anttila et al. examines cancer incidence in 3922 men and 1379
women exposed to styrene, toluene or xylene during the 1973 – 1992 period (2).
The cancer incidence for the entire cohort was the same as that for the general
population. No elevation in cancer risk was seen for xylene exposure. Xylene
exposure was determined by measurement of methylhippuric acid in urine.
In one study with 192 cases of glioma and 343 controls, a significantly elevated
relative risk was observed for men after exposure to organic solvents including
xylene (exposure was classed by an occupational hygienist on the basis of
questionnaires): RR 2.6 (95% CI: 1.3 – 5.2) (77); 38% of the cancer cases and
14% of the controls had been exposed to solvents. When the data were analyzed in
subgroups based on the type of solvent exposure (self-reported), benzene had an
RR of 5.5 (95% CI: 1.4 – 21.3), whereas for xylene (RR 3.3, 95% CI: 0.6 – 18.6),
toluene and trichloroethylene there was not a significant increase in risk. The
numbers of unexposed and exposed subjects in the subgroups were not reported.
No significant increase in relative risk was observed in women, but only 3% of
the women with glioma had been exposed.
The IARC has placed xylene in Group 3: “The agent is not classifiable as to its
carcinogenicity to humans” (41).
Animal data
Groups of rats, 40 of each sex, were given xylene (unspecified) in olive oil, 500
mg/kg b.w., 4 or 5 days/week for 104 weeks. The controls, 50 animals of each
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sex, were given only olive oil. After 141 weeks, when all the animals had died,
13/38 of treated males and 22/40 of treated females were found to have malignant
tumors, compared with 11/45 and 10/49 in controls (60). According to the IPCS, it
is unacceptable to group all the tumors together for analysis – especially when the
animals died of old age (42).
The NTP has made carcinogenicity studies of industrial xylene (9% o-, 60% m-,
14% p-xylene and 17% ethylbenzene) with Fischer-344 rats and B6C3F1 mice.
Groups of 50 animals of each sex were given the xylene (in corn oil) by gavage: 0,
250 or 500 mg/kg b.w. (rats) and 0, 500 or 1000 mg/kg b.w. (mice), 5 days/week
for 2 years. There were no observed treatment-related increases in tumor
incidence when these animals were compared with controls (40, 42).
Effects on reproduction
Human data
Pregnancy outcomes were studied in personnel employed in laboratory work at
Gothenburg University between 1968 and 1979. A questionnaire was sent to 782
women, and the response frequency was 95%. Laboratory work (n = 576) was
associated with a slight but not significant increase in spontaneous abortions (RR
1.31, 95% CI: 0.89 – 1.91). No differences in perinatal death or prevalence of
birth defects were found between babies whose mothers were exposed to solvents
and those of unexposed mothers. No data on xylene exposure is given in the study
(4).
In a Finnish cohort study of laboratory personnel, no correlation was found
between exposure to xylene and birth defects in a case-control analysis, but the
power of the study was low. A case-control study of the cohort, however, revealed
a significant correlation between spontaneous abortions and exposure to xylene
(206 cases and 329 referents, OR 3.1, 95% CI: 1.3 – 7.5). Exposure estimates
were based on job descriptions and made by an occupational hygienist. Mixed
exposures were common (87).
Animal data
Several studies have reported embryotoxic effects (reduced weight, delayed
ossification, increased post-implantation losses) in animals exposed to xylene
by inhalation (34, 39, 63, 78, 90, 91, 92, 93). Elevated frequencies of skeletal
anomalies (extra ribs and “fused sternebrae”) have been reported, but no solid
evidence that xylene caused them. Many of these studies are difficult to assess
because of unclear and incomplete information on maternal toxicity and exposure
conditions.
Hass et al. used neuromotor tests and memory and learning tests to study
postnatal development of rats after prenatal exposure. Their dams had been
exposed for 6 hours/day to 200 ppm industrial xylene (composition not reported)
on days 4 – 20 (34) or 500 ppm industrial xylene (19% o-, 45% m-, 20% p-xylene,
15% ethylbenzene) (35, 36), on days 7 – 20 of gestation. It was observed that on
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day 21 of gestation the fetuses in the 200 ppm exposure group had a higher
frequency of delayed ossification (69%), especially of os maxillaris, than controls
(9%) (34). After the 200 ppm exposure, on days 22 – 24 after birth, the young
were given a neuromotor performance test (Rotarod) in which the time a rat can
remain on a spinning rod was measured. A significantly lower time was observed
for females on days 22 and 23, and for the males on day 23. There were no
indications of maternal toxicity (34). In the follow-up study with 500 ppm
exposure the number of tests was increased, and 15 exposed and 13 unexposed
litters were tested. No indications of maternal toxicity were observed (feed intake,
weight gain, length of gestation, litter size and sex ratios in the litters). The pups
of exposed mothers had later development of the “air righting reflex” and on day
28 post-partum they had significantly lower absolute brain weights. A not
significant trend to lower performance in the Rotarod test was observed on days
24 – 26. At 12 – 14 weeks of age the pups were tested in the Morris water maze,
a test of learning and memory functions in which the rats must find an invisible,
submerged platform (1 cm below the surface) in a round basin. The performance
of the females in the exposed group was significantly worse than that of controls.
In general, the effects were more pronounced in the females (36). The females
were further tested at 28 and 55 weeks of age, and on these occasions also they
did less well than controls in the Morris water maze, although at 55 weeks the
difference was not significant (35).
Pregnant rats were exposed to industrial xylene (15% ethylbenzene, 21% o-,
44% m-, 19% p-xylene), ethylbenzene, o-, m-, or p-xylene (0, 100, 500, 1000 or
2000 ppm) 6 hours/day on days 6 – 20 of gestation. At 1000 and 2000 ppm, the
solvent exposures resulted in lower weight gains in the mothers. Corrected weight
gain (weight minus weight of uterus with fetuses) and food intake were lower at
1000 and 2000 ppm for ethylbenzene, o-, m- and p-xylene, and at 2000 ppm for
industrial xylene. Reduced fetal weights on day 21 of gestation were observed
in the two highest dose groups for all the tested substances, and for o-xylene and
industrial xylene at 500 ppm as well. No indication of teratogenic effects was seen
at any exposure (81).
Dose-response / dose-effect relationships
The most important studies of xylene’s effects are summarized in Table 1 (human
data) and Table 2 (animal data).
For humans, irritation from xylene inhalation has a dose-effect relationship.
Four of six volunteers reported eye irritation with 15 minutes of exposure to
460 or 690 ppm (2000 or 3000 mg/m3). One subject showed symptoms of eye
irritation at 230 ppm (1000 mg/m3) (7). With exposure to 200 ppm xylene
(undefined) for 3 to 5 minutes, more than half of the ten subjects reported
irritation of eyes, nose and throat (66). No eye irritation was observed at 110 ppm
(478 mg/m3) (7). No irritation of eyes, nose or throat was reported by 16 men
who were exposed to 70 ppm (304 mg/m3) p-xylene for 4 hours (1). A significant
increase of discomfort in eyes and nose was reported by 56 subjects exposed to
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50 ppm m-xylene for 2 hours (23). The discomfort levels they marked on the
visual analogue scale ranged from “hardly at all” to “somewhat”.
The RD50 for m-xylene (the concentration that reduces respiratory rate by 50%)
has been reported to be 1360 ppm (5900 mg/m3) for mice. The RD50 is a measure
of sensory irritation of respiratory passages. The ACGIH threshold values based
on irritation are on average about equal to 3% of the RD50 value. For m-xylene
this would be about 40 ppm.
Dose-effect relationships have also been observed for acute CNS effects on
humans. Several studies in which subjects were exposed to 90 – 100 ppm (392 –
470 mg/m3) xylene (15, 82, 83) have shown acute CNS effects on reaction times,
balance, coordination etc. Four hours of inhalation of 70 ppm (304 mg/m3) xylene
in an exposure chamber had no effect on psychophysiological functions (1). A
study by Ernstgård et al. (23) reports that marginal but statistically significant
increases in CNS symptoms (headache, fatigue, nausea, dizziness and feeling of
intoxication) were observed at 50 ppm m-xylene. The symptoms were not severe
and were marked in the “hardly at all” area on the visual analogue scale.
In two epidemiological studies (9, 89) CNS symptoms (nausea, anxiety,
forgetfulness, concentration difficulty) and irritation effects (eye, nose, throat)
are reported at average solvent concentrations of 14 and 4 ppm respectively
(geometric means). The average exposure levels were low in the two studies, but
levels approaching 175 ppm (8-hour time-weighted averages) occurred. These two
studies are difficult to assess, largely due to shortcomings in design – especially
the formulation of the questionnaire and the fact that only a few symptoms
showed the expected dose-response relationship.
Long-term and/or heavy exposure to solvent mixtures containing xylene can
lead to chronic toxic encephalopathy in humans, but the dose-response relation-
ship is poorly known.
In animal experiments, effects on the CNS, considered irreversible, have been
observed after exposure to 100 ppm m-xylene for 4 weeks, and 160 ppm mixed
xylene (18% o-, 70% m-, 12% p-xylene, <3% ethylbenzene, <0.1% toluene) for
4 months (32, 79).
In one study of xylene-exposed persons, a significant correlation was observed
between xylene exposure and subsequent spontaneous abortions. However, only
two cases were exposed to xylene alone (87). Xylene has demonstrated toxic
effects on the reproduction of rats. The pups of rats exposed during gestation
to industrial xylene (inhalation, 200 or 500 ppm) showed effects on development
of the nervous system in various neuromotor, memory and learning tests given
on days 22 – 28 after birth. At the higher dose (not tested at the lower dose),
demonstrable effects persisted to adulthood, and were more pronounced in
the females (34, 35, 36). Lower fetal weights were observed with exposure
to 500 ppm o-xylene or industrial xylene (81).
Xylene is ototoxic to rats at about 800 ppm (3480 mg/m3) (70). There are no
human studies of ototoxicity due to xylene exposure alone.
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Conclusions
The critical effects of occupational exposure to xylene are judged to be irritation
and acute effects on the central nervous system. In an experimental study,
irritation and CNS effects were reported with exposure to 50 ppm m-xylene.
More pronounced irritation of eyes, nose and throat have been reported with brief
exposure to 200 ppm. In other experiments with human subjects, it was found that
exposure to 90 ppm xylene impairs performance on neuropsychological tests.
Exposure to 70 ppm did not affect performance on similar tests.
Chronic toxic encephalopathy (memory and concentration problems, depression
and fatigue) can occur with prolonged and/or heavy exposure to xylene in mix-
tures with other solvents. Dose-response relationships are poorly understood,
however. In animal experiments, CNS effects considered to be permanent have
been demonstrated at exposure to 100 ppm m-xylene and 160 ppm industrial
xylene. There are thus two independent animal studies supporting the conclusion
that chronic CNS effects can arise at 100 – 200 ppm. It is not clear whether these
animal data can be translated to neurotoxic effects on humans.
Effects on the development of the nervous system have been demonstrated in
the young of rats exposed to 200 ppm industrial xylene during gestation.
Skin contact with liquid xylene causes erythema and a burning, stinging
sensation. Repeated skin contact depletes the skin of lipids and results in skin
irritation. Skin exposure to liquid xylene can result in significant systemic
exposure.
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Table 1. Dose-effect relationships observed in studies of persons occupationally exposed
to xylene or exposed in an exposure chamber.
Xylene exposure
 ppm (mg/m3)
No. of subjects,
exposure time
Substance Effects Ref.
4 (17), GM
max 103 (448) TA
233 (122 men,
111 women),
occupational
exposure
Xylene-toluene
mixture
Subjective CNS symptoms;
irritation of eyes, nose, throat
9
14 (60), GM
21 (90), AM
max 175 (760) TA
175 (107 men,
68 women),
occupational
exposure,
average 7 years
The three xylene
isomers together
made up >70% of
the exposure
Subjective CNS symptoms,
irritation of eyes, nose, throat
89
50 (218) 56 (28 men,
28 women)
2 hours
m-xylene Increased subjective discomfort
(CNS effects); irritation of
eyes, nose, throat
23
70 (304) 16 men,
4 hours
p-xylene No negative effect on psycho-
logical tests; no irritation
of eyes, nose, throat
1
90 (392) 8 men,
6 days
m-xylene CNS effects (reaction time,
balance, coordination)
83
100 (434) TA 6 men,
6 hours/day
for 2 weeks
m-xylene CNS effects (reaction time) 82
100 (434) 10 men
4 hours
Not defined,
probably pure
xylene
CNS effects (reaction time) 15
110 (478) 6 volunteers
15 minutes
Mixture: 20%
ethylbenzene
No eye irritation 7
200 (870) 10 volunteers
3 – 5 minutes
Not defined,
probably pure
xylene
More than half the subjects
reported irritation of eyes, nose,
throat
66
460 (2000) 15 minutes Mixture: 20%
ethylbenzene
Eye irritation 7
GM = Geometric mean
AM = Arithmetic mean
TA = Time-weighted averages
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Table 2. Dose-effect relationships observed in animals experimentally exposed to xylenes.
Xylene exp.
ppm (mg/m3)
Species Substance,
exposure time
Effect Ref.
100 (435) Rat m-xylene
6 hrs/day,
5 days/week,
4 weeks
Behavior changes in tests
given 39 to 54 days after
the exposure
32
160 (700) Mongolian
gerbil
18% o-, 70% m-,
12% p-xylene;
<3% ethylbenzene,
<0.1% toluene
4 months
Increase of glial cell
markers and DNA in some
parts of the brain
79
200 (870) Rat Industrial xylene
(unspecified)
6 hrs/day, days
4-20 of gestation
Pups: delayed ossification;
poorer results on learning
and memory tests
34
450 (1960) Rat p-xylene
6 hrs/day,
6 days/week,
13 weeks
No damage to hearing 26
500 (2175) Rat o-xylene or
industrial xylene
(15% ethylbenzene,
21% o-, 44% m-,
19% p-xylene)
6 hrs/day, days 6-20
of gestation
Lower fetal weight on day
21 of gestation
81
500 (2175) Rat Industrial xylene
(unspecified)
6 hrs/day,
days 7-20 of gestation
Pups: Poorer performance
on neuromotor, memory
and learning tests, persisting
to adulthood; more
pronounced for females
35,
36
800 (3480) Rat 10% p-, 80% m-,
10% o-xylene
6 weeks
Hearing damage 70
1360 (5900) Mouse m-xylene RD50 62
4300-6000
(18,700-26,100)
Rat,
Mouse
All 3 isomers
6 hours
LC50 42
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Summary
Montelius J (ed). Scientific Basis for Swedish Occupational Standards. XXVI.
Arbete och Hälsa 2005:17:1-79. National Institute for Working Life, Stockholm.
Critical review and evaluation of those scientific data which are relevant as a background
for discussion of Swedish occupational exposure limits. This volume consists of the
consensus reports given by the Criteria Group at the Swedish National Institute for
Working Life from July, 2004 through September, 2005.
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Sammanfattning
Montelius J (ed). Vetenskapligt underlag för hygieniska gränsvärden. XXVI. Arbete och
Hälsa 2005:17:1-79. Arbetslivsinstitutet, Stockholm.
Sammanställningar baserade på kritisk genomgång och värdering av de vetenskapliga
fakta, vilka är relevanta som underlag för fastställande av hygieniskt gränsvärde.
Volymen omfattar de underlag som avgivits från Kriteriegruppen för hygieniska
gränsvärden under perioden juli 2004 - September 2005.
Nyckelord: Aluminiumtrifluorid, Ammoniumfluorid, Fluorväte, Hygieniskt gränsvärde,
Kalciumfluorid, Kaliumfluorid, Natriumfluorid, Oorganiskt bly,
Riskvärdering, Toxikologi, Vetenskapligt underlag, Xylener.
En svensk version av dessa vetenskapliga underlag finns publicerad i Arbete och Hälsa
2005:16.
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APPENDIX
Consensus reports in this and previous volumes
Substance Consensus date Volume in Arbete
och Hälsa (No.)
Acetaldehyde February 17, 1987 1987:39 (VIII)
Acetamide December 11, 1991 1992:47 (XIII)
Acetic acid June15, 1988 1988:32 (IX)
Acetone October 20, 1987 1988:32 (IX)
Acetonitrile September 12, 1989 1991:8 (XI)
Acrylamide April 17, 1991 1992:6 (XII)
Acrylates December 9, 1984 1985:32 (VI)
Acrylonitrile April 28, 1987 1987:39 (VIII)
Aliphatic amines August 25, 1982 1983:36 (IV)
Aliphatic hydrocarbons, C10-C15 June 1, 1983 1983:36 (IV)
Aliphatic monoketons September 5, 1990 1992:6 (XII)
Allyl alcohol September 9, 1986 1987:39 (VIII)
Allylamine August 25, 1982 1983:36 (IV)
Allyl chloride June 6, 1989 1989:32 (X)
Aluminum April 21, 1982 1982:24 (III)
revised September 14, 1994 1995:19 (XVI)
Aluminum trifluoride September 15, 2004 2005:17 (XXVI)
p-Aminoazobenzene February 29, 1980 1981:21 (I)
Ammonia April 28, 1987 1987:39 (VIII)
Ammonium fluoride September 15, 2004 2005:17 (XXVI)
Amylacetate March 23, 1983 1983:36 (IV)
revised June 14, 2000 2000:22 (XXI)
Aniline October 26, 1988 1989:32 (X)
Anthraquinone November 26,1987 1988:32 (IX)
Antimony + compounds December 8, 1999 2000:22 (XXI)
Arsenic, inorganic December 9, 1980 1982:9 (II)
revised February 15, 1984 1984:44 (V)
Arsine October 20, 1987 1988:32 (IX)
Asbestos October 21, 1981 1982:24 (III)
Barium June 16, 1987 1987:39 (VIII)
revised January 26, 1994 1994:30 (XV)
Benzene March 4, 1981 1982:9 (II)
revised February 24, 1988 1988:32 (IX)
Benzoyl peroxide February 13, 1985 1985:32 (VI)
Beryllium April 25, 1984 1984:44 (V)
Borax October 6, 1982 1983:36 (IV)
Boric acid October 6, 1982 1983:36 (IV)
Boron Nitride January 27 1993 1993:37 (XIV)
Butadiene October 23, 1985 1986:35 (VII)
1-Butanol June 17, 1981 1982:24 (III)
Butanols June 6, 1984 1984:44 (V)
Butyl acetate June 6, 1984 1984:44 (V)
Butyl acetates February 11, 1998 1998:25 (XIX)
Butylamine August 25, 1982 1983:36 (IV)
Butyl glycol October 6, 1982 1983:36 (IV)
γ-Butyrolactone June 2 2004 2005:7 (XXV)
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Cadmium January 18, 1980 1981:21 (I)
revised February 15, 1984 1984:44 (V)
revised May 13, 1992 1992:47 (XIII)
revised February 5 2003 2003:16 (XXIV)
Calcium fluorid September 15, 2004 2005:17 (XXVI)
Calcium hydroxide February 24, 1999 1999:26 (XX)
Calcium nitride January 27, 1993 1993:37 (XIV)
Calcium oxide February 24, 1999 1999:26 (XX)
Caprolactam October 31, 1989 1991:8 (XI)
Carbon monoxide December 9, 1981 1982:24 (III)
Cathecol September 4, 1991 1992:47 (XIII)
Chlorine December 9, 1980 1982:9 (II)
Chlorine dioxide December 9, 1980 1982:9 (II)
Chlorobenzene September 16 1992 1993:37 (XIV)
revised April 2 2003 2003:16 (XXIV)
o-Chlorobenzylidene malononitrile June 1, 1994 1994:30 (XV)
Chlorocresol December 12, 1990 1992:6 (XII)
Chlorodifluoromethane June 2, 1982 1982: 24 (III)
Chlorophenols September 4, 1985 1986:35 (VII)
Chloroprene April 16, 1986 1986:35 (VII)
Chromium December 14, 1979 1981:21 (I)
revised May 26, 1993 1993:37 (XIV)
revised May 24, 2000 2000:22 (XXI)
Chromium trioxide May 24, 2000 2000:22 (XXI)
Coal dust September 9, 1986 1987:39 (VIII)
Cobalt October 27, 1982 1983:36 (IV)
Cobalt and cobalt compounds October 22 2003 2005:7 (XXV)
Copper October 21, 1981 1982:24 (III)
Cotton dust February14, 1986 1986:35 (VII)
Creosote October 26, 1988 1989:32 (X)
Cresols February 11, 1998 1998:25 (XIX)
Cumene June 2, 1982 1982:24 (III)
Cyanamid September 30, 1998 1999:26 (XX)
Cyanoacrylates March 5, 1997 1997:25 (XVIII)
Cycloalkanes, C5-C15 April 25, 1984 1984:44 (V)
Cyclohexanone March 10, 1982 1982:24 (III)
revised February 24 1999 1999:26 (XX)
Cyclohexanone peroxide February 13, 1985 1985:32 (VI)
Cyclohexylamine February 7, 1990 1991:8 (XI)
Desflurane May 27, 1998 1998:25 (XIX)
Diacetone alcohol December 14, 1988 1989:32 (X)
Dichlorobenzenes February 11, 1998 1998:25 (XIX)
1,2-Dibromo-3-chloropropane May 30, 1979 1981:21 (I)
Dichlorodifluoromethane June 2, 1982 1982:24 (III)
1,2-Dichloroethane February 29, 1980 1981:21 (I)
Dichloromethane February 29, 1980 1981:21 (I)
Dicumyl peroxide February 13, 1985 1985:32 (VI)
Dicyclopentadiene March 23, 1994 1994:30 (XV)
Diesel exhaust December 4 2002 2003:16 (XXIV)
Diethanolamine September 4, 1991 1992:47 (XIII)
Diethylamine August 25, 1982 1983:36 (IV)
2-Diethylaminoethanol January 25, 1995 1995:19 (XVI)
Diethylene glycol September 16, 1992 1993:37 (XIV)
Diethyleneglycol ethylether + acetate December 11, 1996 1997:25 (XVIII)
Diethyleneglycol methylether + acetate March 13, 1996 1996:25 (XVII)
Diethyleneglycol monobutylether January 25, 1995 1995:19 (XVI)
Diethylenetriamine August 25, 1982 1983:36 (IV)
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revised January 25, 1995 1995:19 (XVI)
Diisocyanates April 8, 1981 1982:9 (II)
revised April 27, 1988 1988:32 (IX)
Diisopropylamine February 7, 1990 1991:8 (XI)
N,N-Dimethylacetamide March 23, 1994 1994:30 (XV)
Dimethyl adipate December 9, 1998 1999:26 (XX)
Dimethylamine December 10, 1997 1998:25 (XIX)
N,N-Dimethylaniline December 12, 1989 1991:8 (XI)
Dimethyldisulfide September 9, 1986 1987:39 (VIII)
Dimethylether September 14, 1994 1995:19 (XVI)
Dimethylethylamine June 12, 1991 1992:6 (XII)
Dimethylformamide March 23, 1983 1983:36 (IV)
Dimethyl glutarate December 9, 1998 1999:26 (XX)
Dimethylhydrazine January 27, 1993 1993:37 (XIV)
Dimethyl succinate December 9, 1998 1999:26 (XX)
Dimethylsulfide September 9, 1986 1987:39 (VIII)
Dimethylsulfoxide, DMSO December 11, 1991 1992:47 (XIII)
Dioxane August 25, 1982 1983:36 (IV)
revised March 4, 1992 1992:47 (XIII)
Diphenylamine January 25, 1995 1995:19 (XVI)
4,4'-Diphenylmethanediisocyanate (MDI) April 8, 1981 1982:9 (II)
reviderat May 30 2001 2001:20 (XXII)
Dipropylene glycol May 26, 1993 1993:37 (XIV)
Dipropyleneglycol monomethylether December 12, 1990 1992:6 (XII)
Disulfiram October 31, 1989 1991:8 (XI)
Enzymes, industrial June 5, 1996 1996:25 (XVII)
Ethanol May 30, 1990 1991:8 (XI)
Ethanolamine September 4, 1991 1992:47 (XIII)
Ethylacetate March 28, 1990 1991:8 (XI)
Ethylamine August 25, 1982 1983:36 (IV)
Ethylamylketone September 5, 1990 1992:6 (XII)
Ethylbenzene December 16, 1986 1987:39 (VIII)
Ethylchloride December 11, 1991 1992:47 (XIII)
Ethylene December 11, 1996 1997:25 (XVIII)
Ethylene chloride February 29, 1980 1981:21 (I)
Ethylene diamine August 25, 1982 1983:36 (IV)
Ethylene glycol October 21, 1981 1982:24 (III)
Ethylene glycol methylether + acetate June 2, 1999 1999:26 (XX)
Ethyleneglycol monoisopropylether November 16, 1994 1995:19 (XVI)
Ethyleneglycol monopropylether + acetate September 15, 1993 1994:30 (XV)
Ethylene oxide December 9, 1981 1982:24 (III)
Ethylenethiourea September 27, 2000 2001:20 (XXII)
Ethylether January 27, 1993 1993:37 (XIV)
Ethylglycol October 6, 1982 1983:36 (IV)
Ferbam September 12, 1989 1991:8 (XI)
Ferric dimethyldithiocarbamate September 12, 1989 1991:8 (XI)
Flour dust December 10, 1997 1998:25 (XIX)
Fluorides September 15, 2004 2005:17 (XXVI)
Formaldehyde June 30, 1979 1981:21 (I)
revised August 25, 1982 1983:36 (IV)
Formamide December 12, 1989 1991:8 (XI)
Formic acid June 15, 1988 1988:32 (IX)
Furfural April 25, 1984 1984:44 (V)
Furfuryl alcohol February 13, 1985 1985:32 (VI)
Gallium + Gallium compounds January 25, 1995 1995:19 (XVI)
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Glutaraldehyde September 30 1998 1999:26 (XX)
Glycol ethers October 6, 1982 1983:36 (IV)
Glyoxal September 13, 1996 1996:25 (XVII)
Grain dust December 14, 1988 1989:32 (X)
Graphite December 10, 1997 1998:25 (XIX)
Halothane April 25, 1985 1985:32 (VI)
2-Heptanone September 5, 1990 1992:6 (XII)
3-Heptanone September 5, 1990 1992:6 (XII)
Hexachloroethane September 15, 1993 1994:30 (XV)
Hexamethylenediisocyanate (HDI) April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
Hexamethylenetetramine August 25, 1982 1983:36 (IV)
n-Hexane January 27, 1982 1982:24 (III)
2-Hexanone September 5, 1990 1992:6 (XII)
Hexyleneglycol November 17, 1993 1994:30 (XV)
Hydrazine May 13, 1992 1992:47 (XIII)
Hydrogen bromide February 11, 1998 1998:25 (XIX)
Hydrogen cyanide February 7 2001 2001:20 (XXII)
Hydrogen fluoride April 25, 1984 1984:44 (V)
revised September 15, 2004 2005:17 (XXVI)
Hydrogen peroxide April 4, 1989 1989:32 (X)
Hydrogen sulfide May 4, 1983 1983:36 (IV)
Hydroquinone October 21, 1989 1991:8 (XI)
Indium March 23, 1994 1994:30 (XV)
Industrial enzymes June 5, 1996 1996:25 (XVII)
Isocyanic Acid (ICA) December 5 2001 2002:19 (XXIII)
Isophorone February 20, 1991 1992:6 (XII)
Isopropanol December 9, 1981 1982:24 (III)
Isopropylamine February 7, 1990 1991:8 (XI)
Isopropylbenzene June 2, 1982 1982:24 (III)
Lactates March 29, 1995 1995:19 (XVI)
Lactate esters June 2, 1999 1999:26 (XX)
Lead, inorganic February 29, 1980 1981:21 (I)
revised September 5, 1990 1992:6 (XII)
revised December 8, 2004 2005:17 (XXVI)
Lithium and lithium compounds June 4 2003 2003:16 (XXIV)
Lithium boron nitride January 27, 1993 1993:37 (XIV)
Lithium nitride January 27, 1993 1993:37 (XIV)
Maleic anhydride September 12, 1989 1991:8 (XI)
Manganese February 15, 1983 1983:36 (IV)
revised April 17, 1991 1992:6 (XII)
revised June 4, 1997 1997:25 (XVIII)
Man made mineral fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Mercury, inorganic April 25, 1984 1984:44 (V)
Mesityl oxide May 4, 1983 1983:36 (IV)
Metal stearates, some September 15, 1993 1994:30 (XV)
Methacrylates September 12, 1984 1985:32 (VI)
Methanol April 25, 1985 1985:32 (VI)
Methyl acetate March 28 1990 1991:8 (XI)
Methylamine August 25, 1982 1983:36 (IV)
Methylamyl alcohol March 17, 1993 1993:37 (XIV)
Methyl bromide April 27, 1988 1988:32 (IX)
Methyl chloride March 4, 1992 1992:47 (XIII)
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Methyl chloroform March 4, 1981 1982:9 (II)
4,4´-methylene-bis-(2-chloroaniline) February 4 2004 2005:7 (XXV)
Methylene chloride February 29, 1980 1981:21 (I)
4,4'-Methylene dianiline June 16, 1987 1987:39 (VIII)
revised October 3 2001 2002:19 (XXIII)
Methyl ethyl ketone February 13, 1985 1985:32 (VI)
Methyl ethyl ketone peroxide February 13, 1985 1985:32 (VI)
Methyl formate December 12, 1989 1991:8 (XI)
Methyl glycol October 6, 1982 1983:36 (IV)
Methyl iodide June 30, 1979 1981:21 (I)
Methylisoamylamine September 5, 1990 1992:6 (XII)
Methylisoamylketone February 6 2002 2002:19 (XXIII)
Methylisocyanate (MIC) December 5 2001 2002:19 (XXIII)
Methyl mercaptane September 9, 1986 1987:39 (VIII)
Methyl methacrylate March 17, 1993 1993:37 (XIV)
Methyl pyrrolidone June 16, 1987 1987:39 (VIII)
α-Methylstyrene November 1 2000 2001:20 (XXII)
Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
revised September 30, 1998 1999:26 (XX)
Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
MOCA February 4 2004 2005:7 (XXV)
Molybdenum October 27, 1982 1983:36 (IV)
Monochloroacetic acid February 20, 1991 1992:6 (XII)
Monochlorobenzene September 16,1993 1993:37 (XIV)
Monomethylhydrazine March 4, 1992 1992:47 (XIII)
Mononitrotoluene February 20, 1991 1992:6 (XII)
Monoterpenes February 17, 1987 1987:39 (VIII)
Morpholine December 8, 1982 1983:36 (IV)
revised June 5, 1996 1996:25 (XVII)
Naphthalene May 27, 1998 1998:25 (XIX)
Natural crystallinic fibers (except asbestos) June 12, 1991 1992:6 (XII)
Nickel April 21, 1982 1982:24 (III)
Nicotine June 2 2004 2005:7 (XXV)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
Nitrosomorpholine December 8, 1982 1983:36 (IV)
Nitrotoluene February 20, 1991 1992:6 (XII)
Nitrous oxide December 9, 1981 1982:24 (III)
Oil mist April 8, 1981 1982:9 (II)
Organic acid anhydrides, some September 12, 1989 1991:8 (XI)
Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
Pentaerythritol November 16, 1994 1995:19 (XVI)
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999:26 (XX)
Pentyl acetate June 14, 2000 2000:22 (XXI)
Peroxides, organic February 13, 1985 1985:32 (VI)
Phenol February 13, 1985 1985:32 (VI)
Phosphorous chlorides September 30, 1998 1999:26 (XX)
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Phosphorous oxides February 11, 1998 1998:25 (XIX)
Phthalates December 8, 1982 1983:36 (IV)
Phthalic anhydride September 12, 1989 1991:8 (XI)
Piperazine September 12, 1984 1985:32 (VI)
Plastic dusts December 16, 1986 1987:39 (VIII)
Platinum June 4, 1997 1997:25 (XVIII)
Polyaromatic hydrocarbons February 15, 1984 1984:44 (V)
Polyisocyanates April 27, 1988 1988:32 (IX)
Potassium aluminium fluoride June 4, 1997 1997:25 (XVIII)
Potassium cyanide February 7 2001 2001:20 (XXII)
Potassium dichromate May 24, 2000 2000:22 (XXI)
Potassium Fluoride September 15, 2004 2005:17 (XXVI)
Potassium hydroxide Marsh 15, 2000 2000:22 (XXI)
2-Propanol December 9, 1981 1982:24 (III)
Propene September 13, 1996 1996:25 (XVII)
Propionic acid November 26, 1987 1988:32 (IX)
Propylacetate September 14, 1994 1995:19 (XVI)
Propylene glycol June 6, 1984 1984:44 (V)
Propylene glycol-1,2-dinitrate May 4, 1983 1983:36 (IV)
Propylene glycol monomethylether October 28, 1986 1987:39 (VIII)
Propylene oxide June 11, 1986 1986:35 (VII)
Pyridine May 13, 1992 1992:47 (XIII)
Quartz March 13, 1996 1996:25 (XVII)
Resorcinol September 4, 1991 1992:47 (XIII)
Selenium December 11, 1985 1986:35 (VII)
revised February 22, 1993 1993:37 (XIV)
Sevoflurane May 27, 1998 1998:25 (XIX)
Silica March 13, 1996 1996:25 (XVII)
Silver October 28, 1986 1987:39 (VIII)
Sodium cyanide February 7 2001 2001:20 (XXII)
Sodium Fluoride September 15, 2004 2005:17 (XXVI)
Sodium hydroxide August 24, 2000 2000:22 (XXI)
Stearates, metallic, some September 15, 1993 1994:30 (XV)
Stearates, non-metallic, some November 17, 1993 1994:30 (XV)
Strontium January 26, 1994 1994:30 (XV)
Styrene February 29, 1980 1981:21 (I)
revised October 31, 1989 1991:8 (XI)
Sulfur dioxide April 25, 1985 1985:32 (VI)
Sulfur fluorides March 28, 1990 1991:8 (XI)
Synthetic inorganic fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
revised December 3, 2003 2005:7 (XXV)
Synthetic organic and inorganic fibers May 30, 1990 1991:8 (XI)
Talc dust June 12, 1991 1992:6 (XII)
Terpenes, mono- February 17, 1987 1987:39 (VIII)
Tetrabromoethane May 30, 1990 1991:8 (XI)
Tetrachloroethane June 4, 1997 1997:25 (XVIII)
Tetrachloroethylene February 29, 1980 1981:21 (I)
1,1,1,2-Tetrafluoroethane March 29, 1995 1995:19 (XVI)
Tetrahydrofuran October 31, 1989 1991:8 (XI)
Tetranitromethane April 4, 1989 1989:32 (X)
Thioglycolic acid June 1, 1994 1994:30 (XV)
Thiourea December 1, 1987 1988:32 (IX)
revised June 2, 1999 1999:26 (XX)
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Thiram October 31, 1989 1991:8 (XI)
Thiurams, some October 31, 1989 1991:8 (XI)
Tin and inorganic tin compounds October 22 2003 2005:7 (XXV)
Titanium dioxide February 21, 1989 1989:32 (X)
Toluene February 29, 1980 1981:21 (I)
revised February 6 2002 2002:19 (XXIII)
Toluene-2,4-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,6-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,4-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
Toluene-2,6-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
1,1,1-Trifluoroethane February 24, 1999 1999:26 (XX)
Trichlorobenzene September 16, 1993 1993:37 (XIV)
1,1,1-Trichloroethane March 4, 1981 1982:9 (II)
Trichloroethylene December 14, 1979 1981:21 (I)
Trichlorofluoromethane June 2, 1982 1982:24 (III)
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982:24 (III)
Triethanolamine August 25, 1982 1983:36 (IV)
revised October 23 2002 2003:16 (XXIV)
Triethylamine December 5, 1984 1985:32 (VI)
Trimellitic anhydride September 12, 1989 1991:8 (XI)
Trimethylolpropane November 16, 1994 1995:19 (XVI)
Trinitrotoluene April 17, 1991 1992:6 (XII)
Vanadium March 15, 1983 1983:36 (IV)
Vinyl acetate June 6, 1989 1989:32 (X)
Vinyl toluene December 12, 1990 1992:6 (XII)
White spirit December 16, 1986 1987:39 (VIII)
Wood dust June 17, 1981 1982:9 (II)
revised June 25, 2000 2000:22 (XXI)
Xylene February 29, 1980 1981:21 (I)
revised September 14, 2005 2005:17 (XXVI)
Zinc April 21, 1982 1982:24 (III)
Zinc chromate May 24, 2000 2000:22 (XXI)
Zinc dimethyl dithiocarbamate September 12, 1989 1991:8 (XI)
Ziram September 12, 1989 1991:8 (XI)
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